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Chronic enteropathy (CE) in dogs refers to a group of inflammatory conditions of the 
intestinal tract with unknown etiology. However, the occurrence of an aberrant 
immune response to antigens derived from endogenous microbiota is likely to play 
an important role in the pathogenesis of canine CE. Thus, finding inflammatory 
markers that reflect disease severity would be clinically useful. Matrix 
metalloproteinase (MMP) -2 and -9 degrade extracellular matrix under both 
physiological and pathological conditions. Mucosal MMP-2 and -9 activities have 
been reported to be upregulated in the intestine of humans with inflammatory bowel 
disease (IBD) and also in animal models of human IBD. However, their 
identification in the intestinal mucosa of healthy Beagles and their involvement in 
the pathogenesis of canine CE are unknown. Elevated intestinal mucosal levels of 
S100A12 and myeloperoxidase, as markers of gut inflammation, have been reported 
in human patients with IBD. Also, increased concentrations of S100A12 in feces and 
serum have been reported in dogs with CE. However, intestinal mucosal S100A12 
concentrations and MPO activities have not previously been investigated in dogs 
with CE and in healthy Beagles. 
The aims of this project were to validate laboratory methods for the 
determination of MMP-2 and -9, S100A12, and MPO in the intestinal mucosa 
samples of healthy Beagles, to measure their mucosal levels in dogs with CE, and to 
compare these results to healthy Beagles. The project also sought to determine the 
relationship between the levels of the four markers and the canine clinical IBD 
activity index (CIBDAI), histopathologic findings, clinical outcome, and serum 
albumin concentrations in dogs with CE. Intestinal mucosal biopsies were collected 
from 40 dogs with CE (duodenum [n = 35], ileum [n = 12], colon [n = 15], and 
cecum [n = 6]). Stored intestinal tissue samples from 18 healthy Beagle dogs served 
as controls (duodenum, ileum, colon [n = 18, each], and cecum [n = 6]). MMP-2 and 
-9 activities, S100A12 concentrations, and MPO activities were measured using 
gelatin zymography, ELISA, and spectrophotometric methods, respectively. The 
methods for determination of MMP-2 and -9, S100A12, and MPO were successfully 
validated in the intestinal mucosa samples of healthy Beagles.  
Compared to healthy Beagles, mucosal pro- and active MMP-2 positive samples 
were significantly higher in duodenum, ileum, and colon of dogs with CE, while 
mucosal pro-MMP-9 positive samples were significantly higher in the duodenum 
and colon. None of the intestinal mucosal samples in healthy Beagles showed 
gelatinolytic activity corresponding to the control bands of active MMP-2 and -9. In 
dogs with CE, however, mucosal active MMP-9 activities showed a significant 
positive association with the severity of neutrophils infiltration in duodenum, 




Compared with healthy controls, both mucosal S100A12 concentrations and 
MPO activities were increased in the duodenum and colon of dogs with CE, while 
the mucosal MPO activity was also increased in the ileum and cecum. In dogs with 
CE, mucosal S100A12 concentrations had an association with the severity of 
epithelial injury and total histopathological injury in the colon; and with the presence 
of neutrophils and macrophages in the duodenal mucosa or with hypoalbuminemia. 
Moreover, mucosal MPO activity had a relationship with the severity of epithelial 
injury and total histopathological injury in the duodenum of dogs with CE. 
Overall, the results of this project demonstrate an upregulation of mucosal pro- 
and active MMP-2 and pro-MMP-9, S100A12, and MPO in the intestine of dogs 
with CE compared to healthy Beagles and it seems that they are involved in the 
pathogenesis of canine chronic enteropathies. These results provide supporting 
evidence to more deeply assess the clinical utility of MMP-2 and -9, S100A12, and 













This research was performed at the Department of Equine and Small Animal 
Medicine (DESAM), Veterinary Teaching Hospital, University of Helsinki, Finland. 
Canine patients were recruited and sampled at the Veterinary Teaching Hospital. The 
laboratory analyses of MMP-2 and -9 and myeloperoxidase were carried out in the 
Central Laboratory of the Department of Equine and Small Animal Medicine and the 
analysis of S100A12 at the GI Lab, Texas A&M University, Texas, USA.  
My deepest gratitude is owed to my supervisor and the director of my studies 
Professor Thomas Spillmann for the patient guidance, encouragement and advice he 
has provided throughout my time as his student. I have been extremely lucky to have 
a supervisor who cared so much about my work, and my future career as well. 
Words cannot express my sincere appreciation to him for all of his kind help and 
support. I am grateful and honored for being supervised by you, and I highly 
appreciate your friendship. 
A million thanks are also owed to my other supervisor Docent Minna Rajamäki 
for her enormous expertise on matrix metalloproteinases in dogs and also for her 
valuable help in writing process of the articles. She responded to my questions and 
queries so promptly and appropriately. I am also very thankful to my third 
supervisor, Dr. Laura Mäkitalo, for her expertise on matrix metalloproteinases in 
human IBD and kind help in writing of the articles.  
My sincerest thanks go to Professor Satu Sankari, as my co-supervisor and also 
the Director of the DESAM, for her expertise in validation and determination of 
myeloperoxidase in the mucosal samples and also for her generous support and 
encouragement throughout the studies, for her valuable help in writing process of the 
articles and for guiding me in the laboratory. I really appreciate all of her patience 
and kind help throughout the lab analyses.
I am very grateful to my co-author Dr. Pernilla Syrjä, DVM, DECVP, for 
performing histopathological examinations of the intestinal mucosal biopsies and for 
her kind help in writing process of the articles. My most sincere thanks go to Dr. 
Susanne Kilpinen for collecting necropsy and biopsy samples for the study. I truly 
appreciate her help.  
I wish to express my gratitude to our co-partners Professor Jörg M Steiner, 
Professor Romy M Heilmann, Phillip Guadiano, Dr. Jan S Suchodolski and Dr. 
Jonathan Lidbury at GI Lab, Texas A&M University for their excellent and 
constructive cooperation.  
I am very thankful to Professor Karin Allenspach and Professor Mitsuyoshi 
Takiguchi for reviewing this thesis. I am also very grateful and honored that Docent 
Stefan Unterer agreed to serve as my opponent.
I also would like to express sincere thanks to Laura Parikka, Kirsi Laukkanen,
and Kaisa Aaltonen for their technical assistance, to Jouni Junnila and Tommi 
 
6 
Pesonen, 4Pharma, Finland, for performing statistical analysis of the data; to Anna 
Hielm-Björkman for her kind and continuous support, positive and warm attitude; to 
Henna Laurila, Sanna Viitanen and all the vets who helped for collecting the biopsy 
samples, and to Hanna Dyggve and Marcus Candido for their invaluable mental 
support in international congresses  and seminars and for pleasant travel company.  
I would like to thank all dogs and their owners for so kindly providing me the 
data I needed for all the studies. This thesis would definitively not have been 
possible without you. 
I gratefully acknowledge the Finnish Centre for Mobility Exchange (CIMO), 
Finnish Veterinary Foundation, Finnish Foundation of Veterinary Research, 
Chancellor’s Travel Grant and the Doctoral Program in Clinical Veterinary Medicine 
for financial support. 
I express my warmest thanks to my late mother Kafieh Abdollahi Maleki, who 
with her pure love and warm-hearted attitude has supported and guided me during 
every step of my life, but who very sadly passed away while I was completing this 
thesis.  I also thank my father for his support throughout my life and also thank my 
brothers, sisters and my friends for being there whenever I needed them.   
Finally, I want to express my deepest love and thanks to my loving wife, 
Vahideh, for her love, support and encouragement and to dedicate this thesis to both 









List of original publications ...................................................................................... 11
Author's contributions ............................................................................................... 12
Abbreviations ............................................................................................................ 13
1 Introduction ............................................................................................................ 15
2 Review of the literature ......................................................................................... 18
2.1 Canine chronic enteropathies ....................................................................... 18
2.2 Matrix metalloproteinases (MMPs) ............................................................. 20
2.2.1  Overview ................................................................................................ 20
2.2.2 MMP-2 and -9 (gelatinases) and their roles in intestinal      
inflammation .................................................................................................... 22
2.3 S100/calgranulin proteins ............................................................................. 26
2.3.1  Overview ................................................................................................ 26
2.3.2  S100A12 protein .................................................................................... 26
2.4 Myeloperoxidase (MPO) enzyme ................................................................ 29




4 Materials and methods .......................................................................................... 31
4.1 Study population and sample collection ........................................................ 31
4.1.1 Healthy Beagles (study I-IV) ................................................................. 31
4.1.2  Dogs with chronic enteropathies (study III and IV) .............................. 31
4.2 Ethical approval of study protocols ................................................................ 32
4.2.1 Healthy Beagles (study I-IV) ................................................................. 32
4.2.2  Dogs with chronic enteropathies (study III and IV) .............................. 32
4.3 Histopathological examination (study I-IV) .................................................. 33
4.4 Clinical examinations of dogs with enteropathies (study III and IV) .......... 34
4.5 Serum albumin concentrations in dogs with chronic enteropathies 
(study III and IV)……… ..................................................................................... 34
4.6 Gelatin zymography for measuring MMP-2 and -9 activities (study I 
and III)………… .................................................................................................. 35
4.7 Enzyme-linked immunosorbent assay (elisa) for measuring s100a12 
concentrations (study II and IV) .......................................................................... 36
4.8 Spectophotometric method for measuring MPO (study II and IV) ............. 37
4.9 Statistical analysis ........................................................................................ 38
4.9.1  Study I .................................................................................................... 38
4.9.2  Study II .................................................................................................. 38
4.9.3  Study III ................................................................................................. 39
4.9.4  Study IV ................................................................................................. 39
5 Results ................................................................................................................... 40
 
9 
5.1 Study population .......................................................................................... 40 
5.1.1  Study I and II .......................................................................................... 40 
5.1.2  Study III and IV ..................................................................................... 40 
5.2 Mucosal MMP-2 and -9 activities in healthy Beagle dogs (study I) ............ 41 
5.3 Mucosal measuring MMP-2 and -9 activities in dogs with CE (study 
III)……. ................................................................................................................ 44 
5.4 Mucosal S100A12 concentrations in healthy Beagle dogs (study II) .......... 48 
5.5 Mucosal S100A12 concentrations in dogs with CE (study IV) ................... 49 
5.6 Analytical validation of spectrophotometric method for MPO 
measurement (study II) ........................................................................................ 50 
5.7 Mucosal MPO activity in healthy Beagle dogs (study II) ............................ 51 
5.8 Mucosal MPO activity in dogs with CE (study IV) ..................................... 51 
5.9 Histological examination .............................................................................. 52 
5.9.1  Healthy Beagle dogs (study I-II) .......................................................... 52 
5.9.2 Mucosal MMP-2 and -9 activities in relation to histopathologic 
changes in dogs with CE (study III) .............................................................. 53
5.9.3 Mucosal S100A12 concentrations in relation to histopathologic 
changes in dogs with CE (study IV) .............................................................. 53 
5.9.4  Mucosal MPO activity in relation to histopathologic changes 
in dogs with CE (study IV) ............................................................................ 53 
5.10  Mucosal MMP-2 and -9 activities, S100A12 concentrations, and 




5.11  Mucosal MMP-2 and -9 activities, S100A12 concentrations, and 
MPO activities in relation to hypoalbuminemia in dogs with CE (study 
III-IV)…… .......................................................................................................... 59
5.12  Correlation between S100A12 concentrations and MPO activities 
(study IV)……….. .............................................................................................. 60
6 Discussion ............................................................................................................. 61
6.1 Identification of mucosal MMP-2 and -9 activities in the intestine of 
healthy Beagles using gelatin zymography (study I) ……….. ........................... 61
6.2 Mucosal MMP-2 and -9 activities in the intestine of dogs with CE 
(study III)………................................................................................................. 64
6.3 Determination of mucosal S100A12 concentrations and MPO 
activities in the intestine of healthy Beagles (study II) ……….. ........................ 66
6.4 Mucosal S100A12 concentrations and MPO activities in the 
intestine of dogs with CE (study IV) ……….. .................................................... 68
6.5 Limitations……….. ..................................................................................... 71
6.5.1 Study I and II .................................................................................. 71
6.5.2  Study III and IV ............................................................................. 71
6.6 Further research……….. ............................................................................. 72





LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original publications, which are referred to in 
the text by their Roman numerals:
I. Hanifeh M, Rajamäki MM, Mäkitalo M, Syrjä P, Sankari S, Kilpinen S and 
Spillmann T. Identification of Matrix Metalloproteinase-2 and -9 Activities 
within Intestinal Mucosa of Clinically Healthy Beagle Dogs. Journal of 
Veterinary Medical Science. 2014;76(8):1079-85. doi: 10.1292/jvms.13-
0578.
 
II. Hanifeh M, Heilmann R, Sankari S, Rajamäki MM, Mäkitalo L, Syrjä P, 
Kilpinen S, Suckodulski J, Steiner JM and Spillmann T. S100A12 
concentrations and myeloperoxidase activities in the intestinal mucosa of 
healthy Beagle dogs. BMC Veterinary Research. 2015;11:234. 
doi:10.1186/s12917-015-0551-1. 
III. Hanifeh M, Rajamäki MM, Sankari S, Syrjä P, Mäkitalo M, Kilpinen S and 
Spillmann T. Identification of matrix metalloproteinase-2 and -9 activities 
within intestinal mucosa of dogs with chronic enteropathies. Acta Veterinaria 
Scandinavica. 2018;60(1):16. doi:10.1186/s13028-018-0371-y.
IV. Hanifeh M, Sankari S, Rajamäki MM, Syrjä P, Kilpinen S, Suckodulski J, 
Steiner JM, Guadiano P, Lidbury J and Spillmann T. S100A12 
concentrations and myeloperoxidase activities are increased in the intestinal 
mucosa of dogs with chronic enteropathies. BMC Veterinary Research. 
2018;14(1):125. doi:10.1186/s12917-018-1441-0.  
These publications have been reprinted with the kind permission of their copyright 




I The author participated in the experimental design, performed the 
homogenization of the mucosal samples, and collected supernatants 
from the homogenized samples of healthy Beagles. The author 
measured protein concentrations of the supernatants. The author also
prepared polyacrylamide gels and ran the gelatin zymography method 
to determine MMP-2 and -9 activities. The author interpreted the 
results under the supervision of Thomas Spillmann and Minna 
Rajamaki. The author wrote and revised the manuscript.
II The author participated in the experimental design, performed the 
homogenization of the mucosal samples, and collected supernatants 
from the homogenized samples of healthy Beagles. The author 
performed spectrophotometric method for measuring MPO activities. 
S100A12 concentrations were measured at GI Lab, Texas A&M 
University, USA. The author interpreted the results under the 
supervision of Thomas Spillmann, Satu Sankari and Joerg Steiner. The 
author wrote and revised the manuscript.
III The author participated in the experimental design, performed the 
homogenization of the mucosal samples, and collected supernatants 
from the homogenized samples of dogs with CE and healthy Beagles.
The author measured protein concentrations of the supernatants. The 
author also prepared polyacrylamide gels and ran the gelatin 
zymography method to determine MMP-2 and -9 activities in the 
mucosal samples of dogs with CE and healthy Beagles. Collecting 
demographic data from all dogs, and CIBDAI scores and albumin 
concentrations from dogs with CE were also performed by the author.
The author interpreted the results under the supervision of Thomas 
Spillmann and Minna Rajamaki. The author wrote and revised the 
manuscript.
IV The author participated in the experimental design, performed the 
homogenization of the mucosal samples, and collected supernatants
from the homogenized samples of dogs with CE and healthy Beagles.
The author performed spectrophotometric method for measuring MPO 
activities. S100A12 concentrations were measured at GI Lab, Texas 
A&M University, USA. Collecting demographic data from all dogs, 
and CIBDAI scores and albumin concentrations from dogs with CE 
were also performed by the author. The author interpreted the results 
under the supervision of Thomas Spillmann, Satu Sankari and Joerg 




ALCAM Activated leukocyte cell adhesion molecule
ANOVA Analysis of variance 
ARD Antibiotic-responsive diarrhea 
ARE Antibiotic-responsive enteropathy 
AU Arbitrary unit  
BSA Bovine serum albumin 
CCECAI Canine chronic enteropathy clinical activity index
CD Crohn’s disease
CE Chronic enteropathy 
CIBDAI Canine inflammatory bowel disease activity index  
cTLI Canine trypsin-like immunoreactivity  
CV Coefficients of variation 
DAMP Damage associated molecular pattern 
DSS Dextran sodium sulfate
e.g. exempli gratia
ECM Extracellular matrix 
EDTA Ethylenediaminetetraacetic acid 
ELISA Enzyme-Linked immunosorbent assay 
FRD Food-responsive diarrhea  
FRE Food-responsive enteropathy 
GI Gastrointestinal 
H2O2 Hydrogen peroxide
HE Hematoxylin and eosin 
HOCl Hypochlorous acid 
HTAB Hexadecyltrimethylammonium bromide 
i.e. id est 
IBD Inflammatory bowel disease 
IBS Irritable bowel syndrome
IL Interleukin 
IQR Interquartile range  
MAPK Mitogen-activated protein kinases 
MMPs Matrix metalloproteinases 
MPO Myelopreoxidase 
MT-MMPs Membrane-type matrix metalloproteinases  
NF-κB Nuclear factor κB 
O/E Observed to expected ratios 
PBS Phosphate buffered saline 
PCDAI Pediatric Crohn’s disease activity index 
RAGE Receptor for advanced glycation end products 
SD Standard deviation 
 
14 
SRD Steroid-responsive diarrhea 
SRE Steroid-responsive enteropathy 
SNRD Steroid non-responsive diarrhea 
SNRE Steroid non-responsive enteropathy 
TBS Tris buffered saline 
TIMPs Tissue inhibitors of metalloproteinases  
TMB 3,3',5,5'-tetramethylbenzidine substrate 
TNF-α Tumor necrosis factor-alpha 
UC Ulcerative colitis 
WSAVA World small animal veterinary association 









Canine chronic enteropathy (CE) is an umbrella term for a group of  inflammatory 
conditions of the intestinal tract with unknown etiology (Allenspach et al., 2007). 
Canine CE is defined by response to treatment as food-responsive diarrhea or 
enteropathy (FRD or FRE), antibiotic-responsive diarrhea or enteropathy (ARD or 
ARE), steroid-responsive diarrhea or enteropathy (SRD or SRE), or steroid-non-
responsive diarrhea or enteropathy (SNRD or SNRE) (Simpson and Jergens, 2011; 
Dandrieux, 2016). The term inflammatory bowel disease (IBD), synonymous for CE, 
has also been used in dogs (Simpson and Jergens, 2011); however, since human IBD 
and canine CE are not similar, using the term IBD for dogs is regarded as incorrect. 
There is a general consensus that an unfavorable interaction between the mucosal 
immune system, the host genetic susceptibility and environment (e.g. microbial 
antigens and dietary antigens) are potential causative factors in the development of 
chronic gastrointestinal inflammation (German et al., 2003; Jergens et al., 2009; 
Simpson and Jergens, 2011; Jergens and Simpson, 2012; Cassmann et al., 2016).
However, the specific pathways that lead to tissue injury and intestinal inflammation 
in dogs with CE are not fully understood and require further investigation (Simpson 
and Jergens, 2011; Schmitz et al., 2015; Cassmann et al., 2016). 
Matrix metalloproteinases (MMPs) are a group of zinc- and calcium-dependent 
endopeptidases that proteolytically degrade extracellular matrix (ECM). They also 
degrade or activate a diversity of non-matrix substrates such as cytokines, growth 
factors, chemokines, and junctional proteins; therefore, it is likely that they play 
important roles in inflammatory responses (Naito and Yoshikawa, 2005; Ravi et al., 
2007). Among the MMPs, MMP-2 (gelatinase A) and MMP-9 (gelatinase B) have 
been shown to be upregulated in the intestinal mucosa of human patients with 
inflammatory bowel disease (IBD) (Baugh et al., 1999; Kirkegaard et al., 2004; Gao 
et al., 2005; Makitalo et al., 2010) and also in animal models of human IBD (Garg et 
al., 2006; Ravi et al., 2007; Garg et al., 2009). MMP-2 is mainly produced by 
stromal cells and is believed to play a protective role against tissue damage possibly 
by regulation of epithelial barrier function (Garg et al., 2006; Ravi et al., 2007; Garg 
et al., 2009). MMP-9 is mainly produced by neutrophils and plays a crucial role in 
the induction of intestinal tissue inflammation through promoting neutrophils 
migration and defective re-epithelialization (Gao et al., 2005; Garg et al., 2006; Ravi 
et al., 2007; Garg et al., 2009). To our knowledge, there has been no report about 
MMP-2 and -9 activities in the intestinal mucosa of healthy Beagles and dogs with 
CE.
S100A12, also known as calgranulin C, belongs to the S100/calgranulin protein 
family and is mainly expressed and secreted by neutrophils (Vogl et al., 1999; Meijer 
et al., 2014) and macrophages/monocytes (Shiotsu et al., 2011). S100A12 appears to 
play a central role in innate and acquired immune responses (Foell et al., 2007). 
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Releasing S100A12 into the extracellular space and binding with the receptor for 
advanced glycation end products (RAGE) generates pro-inflammatory cytokines, 
induces oxidative stress, and activates nuclear factor κB (NF-κB). This consequently
leads to amplification and perpetuation of the inflammatory response (Hofmann et 
al., 1999; Foell et al., 2007; Pietzsch and Hoppmann, 2009). Concentrations of 
S100A12 have been reported to be increased in serum, feces, and intestinal mucosal
samples from human patients with IBD (Foell et al., 2003b; de Jong et al., 2006; 
Kaiser et al., 2007; Leach et al., 2007; Foell et al., 2008; Sidler et al., 2008; Judd et 
al., 2011; Dabritz et al., 2013). Increased concentrations of S100A12 have been 
reported in the feces and serum of dogs with CE (Heilmann et al.; Grellet et al., 
2013; Heilmann et al., 2014a; Heilmann et al., 2014b; Heilmann et al., 2016b). Fecal 
S100A12 concentration might permit the differentiation of clinical CE subtypes,
since one study showed that the parameter is higher in dogs with SRD than in dogs 
with FRD or ARD. SNRD dogs also carried higher S100A12 concentrations than 
dogs with complete remission after steroid treatment (Heilmann et al., 2016b).
However, when measuring fecal S100A12 concentrations, it is impossible to 
differentiate the region of origin within the intestinal mucosa. Given the various 
physiologic roles of S100A12, it is reasonable to consider this protein’s function in 
the intestinal mucosa during inflammation in dogs with CE. Nonetheless, there is a 
lack of studies determining S100A12 concentrations in the intestinal mucosa of 
healthy Beagles and those with CE.
Myeloperoxidase (MPO) is a peroxidase enzyme mostly found in neutrophils and 
at lower concentrations in monocytes/macrophages and eosinophils (Klebanoff, 
2005; Roncucci et al., 2008; Preiser, 2012). MPO plays an important role in 
intracellular microbial destruction by producing hypochlorous acid (HOCl) from 
hydrogen peroxide (H2O2) and chloride. Extracellularly, it induces oxidative tissue 
damage of host tissue (Klebanoff, 2005; Odobasic et al., 2007). Mucosal MPO 
activity has been reported to be increased in the intestine of human patients with IBD 
(Kruidenier et al., 2003; Kayo et al., 2006; Hegazy and El-Bedewy, 2010; Hansberry 
et al., 2017) and also in animal models of IBD (Kim et al., 2012; Li et al., 2016; Lv 
et al., 2017). Intestinal mucosal MPO activity has not yet been investigated in 
healthy Beagles or dogs with CE. 
It was hypothesized that zymography, ELISA and colorimetric methods can be 
used to reliably determine MMP-2 and -9 activities, S100A12 concentrations, and 
MPO activity, respectively, in canine intestinal mucosal samples. In addition, it was 
also hypothesized that dogs with chronic enteropathies have increased mucosal 
MMP-2 and -9 activities, S100A12 concentrations, and MPO activity in the intestine 
when compared to healthy Beagles.  
Therefore, the objectives of this study were to validate laboratory methods for the 
determination of MMP-2 and -9, S100A12, and MPO in the intestinal mucosa 
samples of healthy Beagle dogs, and then measure their mucosal activities or 
concentrations in dogs with CE and compare the results with healthy Beagles. We 
also evaluated the relationship between MMP-2 and -9, S100A12, and MPO levels 
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with the canine IBD activity index (CIBDAI), histopathologic findings, clinical 
outcome, and serum albumin concentrations in dogs with CE.
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2 REVIEW OF THE LITERATURE 
2.1 Canine chronic enteropathies 
 
Canine chronic enteropathy (CE) is a term used for a group of chronic diseases with 
unknown etiology in small and/or large intestine that may also involve the stomach 
(Allenspach et al., 2007; Simpson and Jergens, 2011). It causes chronic 
gastrointestinal symptoms such as vomiting, diarrhea, tenesmus, hematochezia, 
decreased appetite, and weight loss (Allenspach et al., 2007; Wennogle et al., 2017).  
The diagnosis of canine CE can be achieved by histologic confirmation of an 
idiopathic chronic inflammatory process and the response to treatment trials, such as 
diet change, antibiotic treatment, and anti-inflammatory drug treatment. Treatment 
trials in dogs with CE begin with using diet change (hydrolyzed protein diet or a 
protein restricted diet); and if they respond to diet change alone, they are classified 
as having food responsive diarrhea or enteropathy (FRD or FRE). If nonresponsive 
to dietary changes, antibiotic treatment commences and in case of clinical response 
to metronidazole/tylosin therapy, the CE is classified as antibiotic responsive 
diarrhea or enteropathy (ARD or ARE). Canine patients with CE that failed to 
respond to diet change and antibiotic treatment, but show a clinical response to 
glucocorticoids such as prednisolone, are classified as having steroid responsive 
diarrhea or enteropathy (SRD or SRE) (Allenspach et al., 2007; Simpson and 
Jergens, 2011). Other immunosuppressive drugs that are used to treat canine CE 
include azathioprine, cyclosporine, and chlorambucil (Allenspach et al., 2006; 
Dandrieux et al., 2013). In addition, another group of dogs with CE that fails to 
respond even to immunosuppressive drugs are therefore classified as steroid non-
responsive diarrhea or enteropathy (SNRD or SNRE) (Simpson and Jergens, 2011; 
Dandrieux, 2016). FRD/FRE is the most common form of chronic enteropathies in 
dogs, followed by SRD/SRE and ARD/ARE (Craven et al., 2004; Allenspach et al., 
2007; Allenspach et al., 2016). In contrast to dogs, human inflammatory bowel 
disease (IBD) has two major forms: Crohn’s disease (CD) and ulcerative colitis 
(UC). CD is typically a disease of the ileum and the colon, forming granulomas and 
involving the whole intestinal wall; however, it can also affect other areas of the 
digestive tract. UC is an inflammatory and ulcerative disease usually limited to 
superficial layers (mucosa and submucosa) of the colon and histopathologically 
characterized by infiltration of inflammatory cells (neutrophils, lymphocytes, and 
plasma cells) into the rectal, colonic, and occasionally ileal mucosa (Xavier and 
Podolsky, 2007). 
Interaction between the mucosal immune system, the host genetic susceptibility, 
and microbial and dietary antigens have been identified as potential causative factors 
in the development of chronic enteropathies in dogs (Fig. 1) (German et al., 2003; 
 
19 
Jergens et al., 2009; Simpson and Jergens, 2011; Jergens and Simpson, 2012; 
Cassmann et al., 2016). Maintaining a delicate balance between tolerance and 
responsiveness in the intestinal mucosal immune system is very important and 
disruption of this balance leads to chronic intestinal inflammation (German et al., 
2003; Tanoue et al., 2010). A properly functioning mucosal immune system, the 
mucosal barrier, and the presence of endogenous microbiota are the main elements in 
the maintenance of intestinal  homeostasis (Okumura and Takeda, 2016).  The 
occurrence of an aberrant immune response to endogenous microbiota has been 
proposed to play an important role in the disease pathogenesis of CE in dogs 
(Simpson and Jergens, 2011; Schmitz et al., 2015; Cassmann et al., 2016). Thus, 
phagocyte activation and their biomarkers may represent potential and useful 







Fig. 1. Interaction between four main factors contributing to chronic intestinal inflammation. 
The pathogenesis of canine CE is multifactorial and dysregulated immune response by the 




2.2 Matrix metalloproteinases (MMPs) 
2.2.1 Overview 
Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent endopeptidases 
which are thought to be major contributors to breakdown and reconstitution of 
extracellular matrix (ECM) under both physiological conditions (e.g., tissue 
remodeling during development and growth, intestinal epithelial-cell turnover) and 
pathological conditions (e.g., arthritis, atherosclerotic plaque rupture, tumor 
progression, and IBD) (Medina and Radomski, 2006; Makitalo et al., 2010; 
O'Sullivan et al., 2015).  
To date, more than 24 different MMPs have been identified in humans (Pender et 
al., 1999; Medina and Radomski, 2006). They have been divided into subtypes based 
on substrate specificity and structural homology including the collagenases (MMP-1, 
-8, -13, and -18), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, and -11), 
matrilysins (MMP-7 and -26), metalloelastases (MMP-12, -19, -20 and -28),
membrane-type MMPs (MT-MMPs, including MMP-14, -15, -16, -17, -24, and -25), 
and others (MMP-21, -22, -23, and -27) (Table 1) (Visse and Nagase, 2003; Herouy, 
2004). The MMPs are secreted as latent enzymes and become activated by the action 
of serine proteases and other MMPs that can cleave peptide bonds within the 
prodomain (Sternlicht and Werb, 2001; Medina and Radomski, 2006).
The activity of MMPs is regulated by several types of inhibitors, of which the 
tissue inhibitors of metalloproteinases (TIMPs) and alpha-macroglobulins are the 
most important (Snoek-van Beurden and Von den Hoff, 2005). TIMPs comprise a 
family of four protease inhibitors including TIMP 1, TIMP 2, TIMP 3, and TIMP 4 
(Brew et al., 2000). TIMPs act by forming a 1:1 complex with the highly conserved 
zinc binding site of MMPs and the subsequent MMP-TIMP complex is inactive and 








Table 1. Subtypes of matrix metalloproteinases (MMPs) and their substrates modified after
Herouy (2004) and Kadoglou and Liapis (2004) (Herouy, 2004; Kadoglou and Liapis,
2004).










Collagens (type I, II, III, VI, and X), entactin, and aggrecan
Collagens (type I, II, and III), aggrecan







Gelatin, collagens (type I, IV, V, VII, X, and XI), 
fibronectin, laminin, aggrekan, elastin, tenascin C, and 
vitronektin 
Gelatin, collagens (type IV, V, VII, X, and  XIV), 








Aggrecan, fibronectin, laminin, collagens (type III, IV, IX, 
and X), tenascin C, and vitronectin 
Aggrecan, fibronectin, and type IV collagen 






Aggrecan, fibronectin, laminin, type IV collagen, elastin, 
entactin, tenascin, and vitronectin 














Activator of prommp-2, collagens (type I, II, III), 
fibronectin, laminin-1, and vitronectin 
Activator of prommp-2, fibronectin, tenascin, aggrecan 
Activator of prommp-2, type III collagen, fibronectin
Unknown
Activator of prommp-2











elastin, type IV collagen, fibronectin, laminin, vitronectin, 
proteoglycan
aggrecan, cartilage oligomeric matrix protein 














2.2.2 MMP-2 and -9 (gelatinases) and their roles in intestinal inflammation 
MMP-2 and -9 are also referred to as gelatinases A and B, respectively. Both have 
two pro- and active forms with different molecular weights (pro-MMP-2: 72kDa, 
active MMP-2: 62 kDa, pro-MMP-9: 92 kDa, active MMP-9: 82 kDa). Structurally, 
they consist of three common domains including pro-peptide, catalytic domain, and 
the hemopexin-like c-terminal domain. The catalytic and hemopexin-like c-terminal 
domains are linked via a flexible hinge region. Unlike MMP-2, MMP-9 has an 
additional 56-residue domain—the type V collagen-like domain. Since MMP-2 and -
9 are synthesized as pro (inactive) enzymes, cleavage of the pro-peptide (part of the 
cysteine switch) is essential to activate the protease. To inhibit activation of 
enzymes, conserved cysteine residue in the cysteine switch interacts with the zinc in 
the catalytic domain (Fig. 2) (Van den Steen et al., 2001; McCarty et al., 2012).
For activation of MMP-2, first, a complex of MT1-MMP/MMP-14 and TIMP-2
recruit pro-MMP-2 to the cell surface. Subsequent activation of MMP-2 requires an
active MT1-MMP molecule, autocatalytic cleavage steps, cell-cell clustering, and a 
wild-type activated leukocyte cell adhesion molecule (ALCAM) (Lunter et al., 
2005). Following the activation of pro-MMP-2, the amino terminal propeptide 
cleaves to generate a 64-kDa intermediate form, which later is converted to a 62-kDa 
active form of MMP-2 (Ravi et al., 2007).  
MMP-2 degrades ECM substrates, such as gelatin, type I, IV, V, VII, X, XI 
collagens, elastin, laminin, and fibronectin (Table 1). It is primarily produced by 
stromal cells, including fibroblasts, myofibroblasts, and endothelial cells (Fig. 3) 
(Garg et al., 2006). Intestinal mucosal MMP-2 activities have been reported to be 
upregulated in humans with IBD, and also in animal models of human IBD (Baugh 
et al., 1999; Kirkegaard et al., 2004; Gao et al., 2005; Garg et al., 2006; Garg et al., 
2009; Makitalo et al., 2010). An immunohistochemistry study in human patients 
with CD reported increased MMP-2 localization to epithelial cells, pericryptal and 
subepithelial fibroblasts and myofibroblasts, macrophages, lymphocytes, and 
vascular endothelial cells (Kirkegaard et al., 2004).
In an MMP-2 knockout mouse model of colitis, MMP-2 has been described to 
play a protective role against tissue damage possibly by regulation of epithelial 
barrier function (Garg et al., 2006; Ravi et al., 2007). Epithelial barrier dysfunction 
plays an important role in the pathogenesis of intestinal inflammation. Thus, an 
appropriate function of MMP-2 is a critical host factor to maintain proper epithelial 
barrier function and to prevent intestinal inflammation in the mouse model of IBD 
(Garg et al., 2006; Ravi et al., 2007). However, in humans with IBD, MMP-2 
contributes to the ECM remodeling and degradation of the basal membrane type IV 
collagen leading to intestinal ulceration, epithelial damage, and/or fistula formation 
(Stallmach et al., 2000; Matsuno et al., 2003; McKaig et al., 2003; Gao et al., 2005; 
O'Sullivan et al., 2015).  
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MMP-9 is distinguished from all other MMPs by its highly glycosylated type V 
collagen-like domain. This extra domain affects MMP-9 substrate specificity and 
resistance to degradation by TIMPs. MMP-9 is also synthesized as a pro enzyme 
which requires proteolytic activation (Ravi et al., 2007). MMP-9 activation is 
achieved by an interacting plasmin and MMP-3 (stromelysin 1). Plasmin generates 
active MMP-3 from its zymogen and subsequently active MMP-3 cleaves the 
propeptide from the pro-MMP-9 (92 kDa), yielding an enzymatically active MMP-9
(Ramos-DeSimone et al., 1999). In addition to MMP-3, MMP-2 is also an important 
and potent activator of MMP-9. Moreover, the pro form of MMP-9 alone is able to 
bind and degrade certain types of gelatin (Ravi et al., 2007). 
MMP-9 degrades gelatin, collagens (type IV, V, VII, X, XIV), aggrecan, elastin, 
entactin, and vitronectin (Table 1). It is mainly produced by neutrophils and to a 
lesser extent by macrophages, monocytes, eosinophils, lymphocytes, and epithelial 
cells (Fig. 3) (Kim et al., 2004; Gao et al., 2005; Lubbe et al., 2006; Garg et al., 
2009; Hogan, 2009). Similar to MMP-2, intestinal mucosal MMP-9 activities have 
been reported to be upregulated in humans with IBD and also in animal models of 
human IBD (Baugh et al., 1999; Stallmach et al., 2000; Kirkegaard et al., 2004; Gao 
et al., 2005; Garg et al., 2006; Garg et al., 2009; Makitalo et al., 2010). In both 
humans with IBD and animal models of human IBD, MMP-9 plays a crucial role in 
the induction of intestinal tissue inflammation via promoting neutrophil migration, 
defective re-epithelialization, increased paracellular permeability, and reduction in 
adhesion complex integrity, resulting in impaired wound healing, especially in the
acute phase (Gao et al., 2005; Garg et al., 2006; Ravi et al., 2007; Garg et al., 2009). 
The mechanism by which MMP-9 inhibits wound healing is unknown, however, it 
has been reported to play an important role in the posttranslational regulation of 
cadherin and occludin adhesive activities. Proteolytic cleavage of occludin or E-
cadherin ectodomain by MMP-9, results in tight and adherens junction disassembly 
which leads to impaired cell migration and wound healing. Taken together, MMP-9 







Fig. 2. Structure of MMP-2 and -9 modified after McCarty et al. (2012). Both MMP-2 and -
9 have three common domains including the pro-peptide, catalytic domain, and the 
hemopexin-like c-terminal domain. This hemopexin region is connected to the catalytic 
domain through a flexible hinge domain. For activation of the pro form of MMP-2 and -9, 
the pro-peptide must be cleaved; and for preventing the activation of these enzymes, the 
cysteine switch has a conserved cysteine residue which interacts with the zinc ion in the 





Fig. 3. MMP-2 and -9 cellular sources in human inflammatory bowel disease (IBD) 
modified after Medina and Radonski (2006). Virus, bacteria, or toxins in the intestinal lumen 
can cause immunological responses with activation of different cells, such as neutrophils, 
macrophages, fibroblasts, eosinophils, and T-lymphocytes. These cells release several 
cytokines, such as TNF-α and IL-1, MMP-2 and -9, and other MMPs. In pathological 
conditions, such as IBD, the balance between MMPs and tissue inhibitors of 
metalloproteinases is disrupted, which leads to disturbed extracellular matrix remodeling. 
ECM: extracellular matrix; MMP: matrix metalloproteinase; TNF-α: tissue necrosis factor-α; 







2.3 S100/calgranulin proteins 
2.3.1 Overview 
The S100/calgranulin proteins are a family of low-molecular-weight proteins
consisting of at least 25 different S100 calcium-binding proteins (Manolakis et al., 
2010). In addition to calcium, some S100 proteins can also bind zinc or copper
(Leclerc et al., 2009). They were first identified in 1965 (Moore, 1965). The name 
S100 is derived from the fact that these proteins are 100% soluble in saturated 
ammonium sulfate at neutral pH (Meijer et al., 2012). S100 proteins are encoded by 
a family of genes whose symbols have the S100 as prefix (e.g., S100A1, S100A2, 
S100A3 etc.). All S100 proteins have two EF-hand motifs separated by a linker 
region (α-helix-loop-α-helix) and each motif is able to bind one calcium ion. After 
binding, nearly all S100 proteins undergo a conformational change leading to 
formation of a target recognition site which enables selective interaction with a host 
of specific protein or peptide targets (Leclerc et al., 2009; Meijer et al., 2012).
Besides intracellular functions, three members of the S100 proteins, S100A8 (MRP8, 
calgranulin A), S100A9 (MRP14, calgranulin B), and S100A12 (calgranulin C) also 
have important extracellular activities such as anti-microbial activities, anti-fungal 
properties, inhibition of immunoglobulin production, neutrophil and monocyte 
chemotaxis, induction of apoptosis, and regulation of inflammation (Lopez et al., 
2017).
2.3.2 S100A12 protein 
S100A12, also known as Calgranulin C, belongs to the S100/calgranulin-protein 
family. S100A12 was first identified in the cytosol of human neutrophils and 
monocytes (Guignard et al., 1995). After first description of S100A12 protein in 
humans, it has also been identified later in other mammals, including dogs, pigs,
cows, and rabbits (Yang et al., 1996; Yamashita et al., 1999; Chen et al., 2010; 
Heilmann et al., 2010). It is mainly expressed and secreted by neutrophils (Vogl et 
al., 1999; Meijer et al., 2014) and macrophages/monocytes (Shiotsu et al., 2011). In 
healthy individuals, S100A12 protein is expressed in tissues and organs where 
neutrophils and monocytes/macrophages are common, such as the spleen and lung 
(Meijer et al., 2012). S100A12 plays a key role in intracellular homeostasis and has 
extracellular functions such as anti-microorganism and antiparasitic activities, 
proinflammatory cytokine production, induction of oxidative stress, chemotaxis, and 
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sustained recruitment of leukocytes (Gottsch et al., 1999; Miranda et al., 2001; 
Pietzsch and Hoppmann, 2009). S100A12 also acts as a phagocyte-specific damage
associated molecular pattern (DAMP) molecule. Thus, S100A12 appears to play an 
important role in innate and adaptive immune responses (Foell et al., 2007). After 
the release of S100A12 into the extracellular space, either due to cell damage or 
activation of phagocytes, it acts as a ligand for the receptor for advanced glycation 
end products (RAGE) (Hofmann et al., 1999; Foell et al., 2007). Binding to RAGE 
can induce sustained post-receptor signaling, including activation of nuclear factor 
κB (NF-κB) and the upregulation of transmembrane RAGE itself which can in turn
lead to amplification and perpetuation of the inflammatory response (Hofmann et al., 
1999; Schmidt et al., 2000; Foell et al., 2007; Pietzsch and Hoppmann, 2009) (Fig.
4).
S100A12 concentrations have been reported to be increased in a range of 
inflammatory conditions in humans including cystic fibrosis (Foell et al., 2003c),
rheumatoid arthritis (Foell et al., 2003a; Foell et al., 2004), acute and chronic lung 
diseases (Lorenz et al., 2008), and in patients with IBD (fecal , serum, and intestinal 
mucosa samples) (Foell et al., 2003b; de Jong et al., 2006; Kaiser et al., 2007; Leach 
et al., 2007; Foell et al., 2008; Sidler et al., 2008; Judd et al., 2011; Dabritz et al., 
2013). In human medicine, fecal S100A12 has been reported to be a very sensitive 
and specific marker for distinguishing adult IBD from irritable bowel syndrome 
(Yang et al.) (Kaiser et al., 2007) or pediatric active IBD from those children without 
IBD (Sidler et al., 2008). Serum and mucosal levels of S100A12 were increased in 
children with IBD as compared with non-IBD controls (Leach et al., 2007). Elevated 
levels of S100A12 protein in the colonic mucosa of patients with IBD imply possible 
contribution of S100A12 to the pathogenesis of this disease. 
In dogs, canine S100A12 has been purified (Heilmann et al., 2010), and a 
radioimmunoassay has been developed and validated for its quantification in fecal 
and serum (Heilmann et al., 2011a), and urine samples (Heilmann et al., 2014c). 
Later, an ELISA method was also established and analytically validated for the 
determination of S100A12 concentrations in serum and fecal samples of healthy 
dogs (Heilmann et al., 2016a). S100A12 concentrations have been reported to be 
increased in feces and serum from dogs with CE (Heilmann et al.; Grellet et al., 
2013; Heilmann et al., 2014a; Heilmann et al., 2014b; Heilmann et al., 2016b).
Increased concentrations of fecal S100A12 in dogs with CE had an association with 
the severity of clinical signs, endoscopic lesions, colonic inflammation, and negative 
clinical outcome (Heilmann et al., 2014a; Heilmann et al., 2014b). Fecal S100A12 
concentrations were also measured in dogs with different types of CE, including 
FRD, ARD, SRD, and SNRD (Heilmann et al., 2016b). Elevated levels of fecal 
S100A12 concentrations have been reported in dogs affected with SRD compared to 
those with FRD or ARD; and also in SNRD dogs compared to those experiencing 
complete remission after steroid therapy (Heilmann et al., 2016b). However, when 
measuring fecal S100A12 concentrations, it is impossible to know from which part 
of the intestine they originate. Given the various roles of S100A12, it is reasonable 
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Fig. 4 . S100A12/RAGE interaction modified after Heilmann 2015, p. 21 (Heilmann, 2015). 
This figure shows that S100A12 by binding to the receptor of advanced glycation end 
products (RAGE) can induce sustained post-receptor signaling via activation and 
translocation of nuclear factor-kappa B (NF-κB) and the upregulation of RAGE (positive 
feedback loop), which, in turn, leads to amplification and perpetuation of the inflammatory 
response. MAPK: mitogen-activated protein kinases; PI3K-PKB: phosphatidylinositol-3-
kinase-protein kinase B; NF-κB: nuclear factor-kappa B; RAGE: receptor for advanced 








2.4 Myeloperoxidase (MPO) enzyme 
Myeloperoxidase (MPO) is a peroxidase enzyme which is most abundantly 
expressed in neutrophils and at lower concentrations in monocytes/macrophages and 
eosinophils (Klebanoff, 2005; Roncucci et al., 2008; Preiser, 2012). MPO is 
normally stored in azurophilic granules of the neutrophil; however, it is also released 
into the extracellular space during degranulation. There, it generates hypochlorous 
acid (HOCl) from H2O2 and chloride (Klebanoff, 2005; Roncucci et al., 2008; 
Preiser, 2012). MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl 
radical. Both HOCL and tyrosyl are highly cytotoxic and can be released from the 
cell to destroy foreign microorganisms. However, these toxic agents can also induce 
oxidative tissue damage of host tissue and contribute to inflammation (Odobasic et 
al., 2007; Hansberry et al., 2017).
Increased MPO activity in the intestinal tissue can be utilized as a biomarker of 
oxidative stress and has been described in human patients with IBD (Kruidenier et 
al., 2003; Kayo et al., 2006; Hegazy and El-Bedewy, 2010; Hansberry et al., 2017) 
and also in animal models of human IBD (Kim et al., 2012; Li et al., 2016; Lv et al., 
2017). Elevated levels of mucosal MPO have also been reported to be correlated 
with endoscopic findings in UC and with clinical activity of CD (Kayazawa et al., 
2002).  In addition, Saiki reported a significant elevation of MPO activity in the stool 
samples from active human IBD compared to inactive and healthy controls. The 
author also found an association between MPO with leukocyte counts and the 
endoscopic grade of inflammation (Saiki, 1998). Several studies have shown reduced 
levels of fecal MPO after treatment in human patients with IBD (Peterson et al., 
2007; Wagner et al., 2008). Thus, it seems that the degree of responsiveness to IBD 
treatment can be monitored in people with levels of fecal MPO activity. As a result, 
MPO has the potential to serve as a viable, noninvasive biomarker for assessing 
human IBD status. These findings, however, pose the question of whether mucosal 
MPO activity also has a relationship with canine CE. In canine CE, the predominant 
inflammatory cells are thought to be lymphocytes and plasma cells. However, 
German et al. revealed a significant increase in the number of neutrophils and 
macrophages in dogs with ARD and SRD when compared to healthy controls 
(German et al., 2001). To our knowledge, intestinal mucosal MPO activity has not 
yet been investigated in dogs with CE and healthy Beagles and further research is 
needed to clarify its role in the pathogenesis of canine CE. 
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3 HYPOTHESIS AND AIMS OF THE THESIS 
The main hypothesis of this thesis investigation was that MMP-2 and -9 activities, 
S100A12 concentrations, and MPO activities can be reliably determined using 
zymography, ELISA, and colorimetric methods, respectively, in canine intestinal 
mucosal samples. It is also hypothesized that dogs with chronic enteropathies have 
increased mucosal MMP-2 and -9 activities, S100A12 concentrations, and MPO 
activity in the intestine when compared to healthy Beagles.  
The first two objectives of this PhD thesis were to validate laboratory methods 
for the determination of MMP-2/-9, S100A12, and MPO in the intestinal mucosa 
samples of healthy Beagles. The second two objectives were to measure the MMP-
2/-9, S100A12, and MPO activities or concentrations in the intestinal mucosa of 
dogs with CE and to compare them with results of healthy Beagles. In addition, the 
association of MMP-2/-9, S100A12, and MPO levels with the CIBDAI, 
histopathologic findings, clinical outcome, and serum albumin concentrations in 
dogs with CE were evaluated. In this PhD thesis, it was hypothesized that mucosal 
MMP-2 and -9 activities, S100A12 concentrations, and MPO activities are increased 
in dogs with CE compared to healthy Beagles.
 
Detailed objectives were as follows: 
I. To validate a gelatin zymography method for the determination of MMP-2 and -9
activities in the intestinal mucosa samples of healthy Beagles. 
 
II. To validate ELISA and spectrophotometric methods for the determination of 
S100A12 concentrations and MPO activities in the intestinal mucosa samples of 
healthy Beagles. 
 
III. To investigate mucosal pro- and active MMP-2 and -9 activities in dogs with CE 
and healthy Beagles using gelatin zymography, and also to determine the association 
of their activities in CE dogs with CIBDAI, histopathologic findings, clinical 
outcome, and hypoalbuminemia.
IV. To investigate mucosal S100A12 concentrations and MPO activities in dogs with 
CE and healthy dogs using ELISA and spectrophotometry; and to determine the 
association of their concentrations and activities in CE dogs with CIBDAI, 
histopathologic findings, clinical outcome, and hypoalbuminemia. 
 




4 MATERIALS AND METHODS 
4.1 Study population and sample collection 
4.1.1 Healthy Beagles (study I-IV) 
 
For the validation of the laboratory methods, stored intestinal tissue samples were 
used that had been taken from 18 healthy laboratory Beagle dogs which underwent 
post-mortem examinations when finishing another unrelated study. The dogs were 
housed according to the European Union guidelines in groups in indoor pens with 
access to outdoor runs. The indoor environmental temperature was maintained 
between 15ºC to 24ºC. The dogs were exposed to both natural and artificial light 
from 7:00 to 16:00 and were fed a standard commercial diet. All dogs were 
considered healthy based on history, physical examination, complete blood count, 
serum biochemistry, fecal examination, and histologic evaluation. Immediately after 
euthanasia, the intestine was opened longitudinally and flushed with cold saline. For 
study I and II, full-thickness tissue samples were collected from duodenum, jejunum, 
ileum, and colon (n = 12, each); and for study III and IV, from duodenum, ileum, 
and colon (n = 18, each), and cecum (n = 6)]. Then, all samples were snap frozen in 
liquid nitrogen and stored at -80°C until further analysis. Later, the intestinal mucosa 
was separated from the underlying muscularis layer in the snap-frozen intestinal 
tissue samples and stored at -80°C for gelatin zymographic, ELISA, and 
spectrophotometric analyses. For histopathological examination, snap-frozen full-
thickness intestinal tissue samples were first melted and fixed in formalin and then 
were embedded in paraffin wax.  
 
4.1.2 Dogs with chronic enteropathies (study III and IV) 
 
For study III and IV, 52 dogs with chronic gastrointestinal signs were enrolled into 
our study were enrolled into our study over a 4-year period and routine 
gastroduodenoscopy and/or colonoscopy were performed at the Small Animal 
Teaching Hospital, Faculty of Veterinary Medicine, University of Helsinki, Finland.  
Inclusion criteria for canine patients were having chronic GI signs such as 
vomiting, diarrhea, tenesmus, hematochezia, and/or weight loss for more than 3 
weeks. For each dog, diagnostic tests were performed to exclude underlying 
infectious or extraintestinal disorders. These tests included complete blood count, 
serum biochemical analysis, fecal examination for parasites, abdominal ultrasound,
and gastroduodenoscopy or colonoscopy (or both) with biopsy. The diagnosis of 
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chronic enteropathy was based on previously published clinical, laboratory, 
endoscopic, and histopathologic criteria (Day et al., 2008; Washabau et al., 2010). 
Before starting any treatment, all dogs with chronic GI signs underwent endoscopic 
examination. The area of endoscopy was selected based on the clinical signs. 
Intestinal mucosal biopsies from dogs with chronic GI signs were collected over a 4-
year period and were stored at -80ºC for 1-4 years for MMP-2, MMP-9, S100A12 
and MPO determinations. Group distribution and inclusion/exclusion criteria of all 




Fig. 5. Flow diagram of enrolled dogs. Flow diagram showing group distribution and 
inclusion and exclusion criteria of all dogs enrolled in the study. CE: chronic enteropathies
4.2 Ethical approval of study protocols  
4.2.1 Healthy Beagles (study I-IV) 
 
We used stored intestinal tissue samples taken from 12 (for study I and II) and 18 
(for study III and IV) healthy laboratory Beagle dogs after finishing other non-
related studies. These studies were ethically approved by the Finnish National 
Animal Experiment Board (study license numbers:  ESLH-2007-09833/ Ym-23
ESAVI 2010-04178/Ym-23 and ESAVI/7290/04.10.03/2012).
4.2.2 Dogs with chronic enteropathies (study III and IV) 
The clinical trial involving dogs with chronic enteropathies (study III and IV) were 
ethically approved by the same authority under the license numbers 
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ESAVI/6973/04.10.03/2011 and ESAVI/10384/04.10.07/2014. Informed owner 
consent was obtained at the time the dogs were enrolled for gastroduodenoscopy, 
colonoscopy, or both.  
4.3 Histopathological examination (study I-IV) 
 
For histopathological evaluation of the intestinal tissue samples from healthy 
Beagles, parts of the frozen intestinal tissue samples were later slowly thawed and 
fixed in 4% formaldehyde solution in phosphate buffered saline (PBS) at 8°C under 
permanent automatic rotation of the sample tube. Then, the samples were trimmed 
and paraffin wax embedded. Sections (3–5 μm) were prepared and stained with 
hematoxylin and eosin for histopathological examination. In canine patients with 
CE, the collected intestinal mucosal biopsy samples were fixed in 4% formaldehyde 
solution in phosphate buffered saline, embedded in paraffin, sectioned (3–5 μm), and 
stained with hematoxylin and eosin (HE) for histopathological examination.   
Histopathological assessment of the intestinal samples was evaluated and scored 
by a single pathologist (PS) using the guide lines of the World Small Animal 
Veterinary Association (WSAVA) Gastrointestinal Standardization Group (Day et 
al., 2008; Washabau et al., 2010). In every case, the pathologist was blinded to the 
results of clinical and laboratory examinations and to mucosal levels of MMPs,
S100A12 and MPO. In brief, for the duodenal samples, five morphological features 
(villous stunting, epithelial injury, crypt distention, lacteal dilation, and mucosal 
fibrosis) and five types of infiltrated leukocytes (intraepithelial lymphocytes, lamina 
propria lymphocytes, lamina propria eosinophils, lamina propria neutrophils, and 
lamina propria macrophages) were evaluated and scored from 0 to 3. In the colonic 
samples, four morphological features (epithelial injury, crypt hyperplasia, crypt 
dilation/distortion, and fibrosis/atrophy) and four types of infiltrated leukocytes 
(lamina propria lymphocytes, lamina propria eosinophils, lamina propria neutrophils, 
and lamina propria macrophages) were assessed and scored. The samples from ileum 
and cecum were examined and scored using the guidelines provided for the 
interpretation of duodenal and colonic biopsies, respectively; this was performed 
because of the absence of specific templates for these intestinal segments in the 
WSAVA Gastrointestinal Standardization Group guidelines (Day et al., 2008; 
Washabau et al., 2010). The severity of histopathological changes in different parts 
of the intestine was evaluated and scored as normal = 0, mild = 1, moderate = 2, or 
severe = 3. The total histopathological injury score was defined as the sum of the 
morphology and inflammatory scores and was classified as insignificant (total score 
0–4), mild (total score 5–9), moderate (total score 10–14), severe (total score 15–19),





4.4 Clinical examinations of dogs with chronic enteropathies 
(study III and IV) 
 
The clinical disease activity in dogs with CE was determined based on the CIBDAI 
scoring system at the start of the study and after treatment (Jergens et al., 2003).
Briefly, CIBDAI was assessed using six prominent GI signs (i.e., attitude and 
activity, appetite, vomiting, stool consistency, stool frequency, and weight loss) and 
were scored based on their severity from 0 to 3. The total CIBDAI score represents 
the sum of all individual scores and was classified as insignificant (score 0-3), mild 
(score 4-5), moderate (score 6-8), or severe (score ≥ 9). Recording the CIBDAI score 
before and after treatment was only possible in 30 of 40 dogs with CE and was based 
on either available scores taken by the responsible clinician before and after 
treatment (in 13/30 and 5/30 of dogs, respectively) or calculated retrospectively by 
the investigators (in 17/30 and 25/30 of dogs, respectively) For retrospectively 
calculated scores, information was obtained from clinical history (before treatment) 
and phone interviews with the owners (after treatment). The treatment follow up of 
patients were not based on a standardized time frame and the second CIBDAI was 
either based on control visits or phone calls at least two weeks apart from the start of 
the treatment. The type of CE was determined by response to treatment and since not 
all included dogs developed diarrhea as a clinical sign, the CE type was defined as 
food-responsive enteropathy (FRE), antibiotic-responsive enteropathy (ARE), 
steroid-responsive enteropathy (SRE), or steroid non-responsive enteropathy 
(SNRE) (Simpson and Jergens, 2011; Dandrieux, 2016). As antibiotic, Tylosin at a 
dose of 25mg/kg/day for 7 days was mainly used (Kilpinen et al., 2011). In some 
canine patients also metronidazole with/without enrofloxacin was used. For all three 
SNRE dogs, anallergenic diet (Royal Canin®) was started first, followed by 
antibiotic trial and consecutive prednisolone in two, but immediate prednisolone in 
the third dog. All owners opted for euthanasia due to severity of clinical signs and 
unfavorable response. 
4.5 Serum albumin concentrations in dogs with chronic 
enteropathies (study III and IV) 
 
The serum albumin concentration was determined in each dog with CE. A serum 





4.6 Gelatin zymography for measuring MMP-2 and -9
activities (study I and III) 
The analysis was performed at the Central Laboratory of the Department of Equine 
and Small Animal Medicine (DESAM), University of Helsinki.  In the first step, 
snap-frozen intestinal mucosal samples from healthy Beagle dogs and dogs with CE 
were homogenized for 2 × 50 seconds with 5000 × g in ice-cold extraction buffer at 
a ratio of 20:1 extraction buffer to tissue using Precellys 24 ceramic beads (Bertin 
technologies, Paris, France) (Castaneda et al., 2005). The extraction buffer contained 
50 mM Tris Base, 150 mM NaCl, 10 mM CaCl2, 0.2 mM NaN3, and 0.01% Triton 
X-100 (pH 7.6) in the presence of EDTA-free protease cocktail tablets (1 tablet/50ml 
of extraction buffer or 1 mini tablet/10 ml extraction buffer) (Roche, Basel, 
Switzerland). To prevent temperature rising during the lysis process and to protect 
sensitive molecules from degradation, cold air (-50°C) was sprayed by Cryolys 
device (Bertin technologies) beside the tubes so that temperature during 
homogenization remained at approximately 4°C. After homogenization, samples 
were centrifuged at 13 000 × g at 4°C for 10 min, and the supernatants were 
collected and stored at -80°C for measurement of MMP-2 and MMP-9 (Medina et 
al., 2006). Protein concentrations of the supernatants were measured with 
bicinchoninic acid protein assay reagents (Pierce, Rockford, IL, USA).   
Gelatinolytic activities of MMP-2 and MMP-9 in supernatant were measured by 
gelatin zymography in mini-gels as previously described in detail (Ljungvall et al., 
2011). Supernatants were separated by electrophoresis in 11% polyacrylamide gel 
impregnated with 0.7 mg/ml of gelatin as a substrate (porcine skin gelatin, G-8150, 
Sigma, St. Louis, MO, USA) under non-reducing conditions. Each lane of an 11% 
SDS-polyacrylamide gel was loaded with 20 μl of supernatants containing either 10 
μg or 25 μg of total protein mixed with a 10 μl aliquot of loading buffer. All samples 
were analyzed in duplicate and averaged. Loading buffer consisted of 0.04 g/l 
bromophenol blue (Art. 8122) (BDH), 20% glycerol, and 6% sodium dodecyl 
sulphate (SDS, Prod. 44244) (BDH) at pH 6.8. Electrophoresis was performed by 
using a mini-PROTEAN Tetra Cell electrophoresis system (Bio- Rad Laboratories, 
Hercules, CA, USA) under a constant current of 60 MA for 10 min and then 30 MA 
until the bromophenol blue reaches the bottom of the gel. After electrophoresis, the 
gels were washed in distilled water and then soaked (2 × 30 min) in renaturing buffer 
(2.5% Triton X-100) with gentle shaking at room temperature in order to remove the 
sodium dodecyl sulfate. Then, the gels were soaked in zymogram developing buffer 
(50 mM Tris Base, pH 7.5 containing 200 mM NaCl, 5 mM CaCl2.2H2O and 0.02% 
Brilj-35) for 30 min at room temperature, then replaced with fresh developing buffer 
and incubated for another 18 h at 37°C. Zymogram developing buffer contains 
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divalent metal cations, which are required for enzymatic activation of both the pro 
and active enzymes. After washing the gels with distilled water 3 times for 10 min, 
they were stained with PageBlue™ Protein Staining Solution (Fermentas) and 
stained with gentle agitation for 5 hr. The areas of proteinase activity were visualized 
as clear bands by washing the gels with distilled water. 
As a control, each gel was loaded with diluted (1:600) recombinant human 
MMP-2 and -9 (R&D Systems, Minneapolis, MN, USA), respectively.  For 
quantification of gelatin degradation, gels were scanned and were assessed by 
densitometer analysis method creating an arbitrary unit (AU) for each band by 
calculating the integrated area under each peak (Alpha-imager densitometer, Alpha 
Innotech, San Leandro, CA, USA). The activity levels of pro- and active MMP-2 and
-9 for each sample were expressed in AU related to the level of pro-MMP-2 of the 
positive-control standard loaded on each gel. Each band’s activity was reported as 
the mean of two different measurements of the same sample.  
4.7 Enzyme-linked immunosorbent assay (ELISA) for 
measuring S100A12 concentrations (study II and IV) 
Snap-frozen intestinal mucosal samples from dogs with CE and healthy Beagles 
were sent frozen to GI Lab, Texas A&M University, Texas, USA. All samples were 
homogenized using a Polytron homogenizer in ice-cold extraction buffer (containing 
50 mM Tris/HCl base, 150 mM NaCl, 10 mM CaCl2, 0.2 mM NaN3 and 0.01% (v/v) 
Triton X-100; pH 7.6) in the presence of EDTA-free protease inhibitor cocktail 
tablets (1 tablet/50 ml of extraction buffer or 1 mini tablet/10 ml extraction buffer) at 
a ratio of 20:1 extraction buffer to tissue. After homogenization, samples were 
centrifuged at 13 000 × g and 4°C for 10 min, and the supernatants were collected 
and stored at −80°C for the measurement of S100A12.  
The S100A12 concentrations were determined in the intestinal mucosal samples 
obtained from healthy Beagle dogs and dogs with CE using the ELISA method. The 
ELISA was previously developed and validated in canine serum and fecal samples 
(Heilmann et al., 2016a). Briefly, immunoassay plates were coated with 200 ng/well 
of affinity-purified polyclonal anti-canine S100A12 antibody and were blocked with 
25 mM Tris-buffered saline (TBS), 150 mM NaCl, 0.05% (v/v) polyoxyethylene-20 
sorbitan monolaurate, and 10% (weight/volume [w/v]) bovine serum albumin (BSA) 
at pH 8.0. Plates were then incubated with duplicates of standard canine S100A12 
solutions, assay controls, or mucosal extracts diluted in 25 mM TBS, 150 mM NaCl, 
0.05% polyoxyethylene-20 sorbitan monolaurate, and 0.5% (w/v) BSA at pH 8.0. To 
detect captured antigens, plates were incubated with horseradish peroxidase-labeled 
anti-canine S100A12 polyclonal antibody (15 ng/well), and developed with a 
stabilized 3,3',5,5'-tetramethylbenzidine substrate (TMB). After 5-min incubation 
with TMB, color development was stopped with 4 M acetic acid and 0.5 M sulfuric 
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acid. Absorbance was measured at 450 nm. The lower detection limit of the ELISA 
assay for canine S100A12 was determined by calculating the mean response + 3 
times the standard deviation for 20 replicates of the blank solution. S100A12 
concentrations in extracts of snap-frozen intestinal mucosal tissues were measured 
using the same lot of reagents for all samples and are reported as μg/L of the 
intestinal mucosal supernatant.
4.8 Spectophotometric method for measuring MPO (study II 
and IV) 
For measuring mucosal MPO activity at the Central Laboratory of DESAM, 
University of Helsinki, snap-frozen intestinal mucosal samples from healthy Beagles 
and dogs with CE were weighed, suspended in ice-cold extraction buffer at a ratio of 
20:1 of extraction buffer to tissue, and homogenized for 2 × 50 seconds at 5000 × g
using Precellys 24 ceramic beads at 4°C (Bertin technologies, France). The 
extraction buffer contained hexadecyltrimethylammonium bromide (HTAB; 0.5% 
w/v) in a 50 mM sodium phosphate buffer (pH 5.4). After homogenization, samples 
were centrifuged at 4000 × g and 4°C for 20 min, and the supernatants were 
collected and stored at -80°C.  
MPO activity was determined in intestinal mucosa using the method described by 
Marquez and Dunford (Marquez and Dunford, 1997) with the modification that the 
final assay buffer was supplemented with HTAB as a cationic detergent. Briefly, the 
reaction mixture consisted of 170 μL of sodium phosphate buffer (80 mM, pH 5.4) 
with HTAB (0.5% w/v) and TMB (1.6 mmol/L). Five μL of supernatant and 5 μL of 
distilled water were added to this reaction mixture, and the mixture was incubated at 
37°C for 6 min, after which 20 μL of H2O2 (0.3 mmol/L) was added. After the 
addition of H2O2, a kinetic measurement for 60 seconds was started at a wavelength 
of 620 nm using an automated biochemical analyzer (Konelab 30i, Thermo Fisher 
Scientific, Vantaa, Finland). The researchers performing the laboratory analysis (MH 
and SS) were blinded to the individual dog’s clinical data (ie, health status, clinical 
outcome, and intestinal segment). The lower detection limit of the 
spectrophotometric assay for mucosal MPO was calculated based on the following 
formula: mean blank + 3 × SD for 7 replicates of the blank solution. MPO activity 
was expressed as the delta absorbance units per minute (ΔA/min) in 5 μL of 
supernatant. 
For study II, the colorimetric method for MPO determination was validated for 
precision, accuracy, and recovery. Intra- and inter-assay precisions were determined 
as coefficients of variation calculated from six different small and large intestinal 
mucosa samples within one analytical run (n = 10) and across different runs (n = 10). 
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The linearity was evaluated using serial dilutions of the same mucosal samples (1:2, 
1:4, 1:8 and 1:16) standard deviation (SD) of the observed and expected ratios (%). 
The spiking recovery was analyzed among six different spiking activity samples of 
human MPO-pure enzyme (0.066, 0.109, 0.161, 0.191, 0.318 and 0.477 ΔA/min) in 
five different small and large intestinal mucosa samples. The mean and SD values 
were calculated for the observed and expected ratios (%). 
4.9 Statistical analysis  
 
For all analyses, we considered values of P < 0.05 as significant. All statistical 
analyses were performed using the SAS 9.3 statistical software (SAS Institute Inc., 
Cary, NC, USA).
4.9.1 Study I 
The differences between the separate parts of the intestine (duodenum, jejunum, 
ileum and colon) in their proportions of samples with pro-MMP-2 and -9 activities 
were analyzed with exact McNemar’s test. Bonferroni adjustment was used to 
control for multiplicity issues. Data are presented as number (%) or median (range) 
as appropriate.  
4.9.2 Study II
 
Data are presented as medians (interquartile range). The differences in the S100A12 
concentrations and MPO activities between the four different segments of the 
intestine (duodenum, jejunum, ileum, and colon) were analyzed using an analysis of 
variance (ANOVA) model. To satisfy the assumptions of normality and the 
homogeneity of variances, the original values were transformed to a logarithmic 
scale. If the results of the Levene’s test were significant (P < 0.05) following data 
transformation, an ANOVA-Welch test was used for further analysis. The fitted 
model included the section of intestine as the fixed effect and the dog as the random 
effect. Tukey’s HSD test was used in pairwise comparisons to control for multiple 
comparisons, and Tamhane’s T2 test was used for variables with significant 






Data are presented as number (%) or median (range) as appropriate. The differences 
between pro- and active MMP-2 and -9 positive samples in different intestinal 
segments (duodenum, ileum, colon, and cecum) between dogs with CE and healthy 
Beagles were analyzed using Fisher’s exact test. Association of CIBDAI score and 
pro- and active MMP-2 and -9 activities was evaluated using Spearman correlation 
test.  The same test was used to analyze correlation between hypoalbuminemia and 
pro- and active MMP-2 and -9 activities in dogs with CE. Kruskal-Wallis test was 
used to analyze association between pro- and active MMP-2 and -9 activities and 
histopathological changes and clinical outcome (FRE, ARE, SRE, and SNRE) in 
dogs with CE. 
4.9.4 Study IV
 
To satisfy the assumptions of normality and the homogeneity of variances, the 
original values of S100A12 and MPO were transformed to a logarithmic scale. The 
normality of log-transformed values was then confirmed by Shapiro-Wilk test. The 
differences between S100A12 concentrations and MPO activities in different 
intestinal segments (duodenum, ileum, colon, and cecum) between dogs with CE and 
healthy Beagles were determined using Student's t-tests. An analysis of variance 
(ANOVA) test was used to determine the association between S100A12 
concentrations and MPO activities with total histopathological injury severity 
(insignificant, mild, moderate, or severe) and individual histopathological changes 
severity (normal, mild, moderate, or severe). A Spearman’s correlation coefficient 
was used to determine a potential correlation between S100A12 concentrations and 
MPO activities in dogs with CE and healthy Beagles. A possible correlation between 
CIBDAI score and S100A12 concentrations or MPO activities was tested using 
linear regression. The generalized logit-model was used to determine a possible 
association between S100A12 concentrations and MPO activities with clinical 
outcome (ie, FRE, ARE, SRE, or SNRE) in dogs with CE. All statistical differences 
were calculated based on the log-transformed values of S100A12 and MPO, and 
presented as mean and standard deviation in figures. However, untransformed values 
are presented as median (interquartile range: IQR) or median (range) as appropriate, 
for ease of interpretation in tables and texts. No adjustment was made for multiple 




5.1 Study population 
5.1.1 Study I and II
The median age (range) of healthy Beagle dogs was 11 years (10-13), 8 dogs were 
intact females and 4 dogs were intact males.
5.1.2 Study III and IV
 
The median age (range) of dogs with CE and healthy Beagles were 5 years (1–13
years) and 10.5 (6-13), respectively.  In the CE group, 15 dogs were intact males, 11 
dogs were castrated males, 5 dogs were intact females, and 9 dogs were spayed 
females. In the healthy Beagle control group, 8 dogs were intact males and 10 dogs 
were intact females. The breeds of dogs with CE were mixed breed (6), Rottweiler 
(2), German Shepherd dog (2), Shetland Sheepdog (2), Parson Russell Terrier (2), 
Rough Collie (2), Standard Poodle (2), and one each of the following: Alaskan 
Malamute, Bichon Frise,  Border Terrier, Chow Chow, Dalmatian, English Bulldog, 
Golden Retriever, Havanese, Irish Terrier, Jack Russell Terrier, Long-haired 
Dachshund, Mudi, Norwegian Lundehund, Rhodesian Ridgeback, Siberian Husky,
Silky Terrier, Smooth Collie, Spanish Water Dog, Staffordshire Bull Terrier, Toy 
Poodle, West Highland White Terrier, and White Shepherd dog. 
Out of 52 dogs, 12 displaying chronic GI signs were excluded from further 
analysis. Seven dogs had gastrointestinal neoplasia (ie, 3 gastric adenocarcinomas, 2 
lymphomas, 1 rectal plasma cell tumor, and 1 rectal adenocarcinoma). Four dogs had 
primary esophageal disorders, and one was positive for Giardia on fecal 
examination. A total of 40 dogs with CE were included in the study for analysis. 
Twenty-five dogs underwent gastroduodenoscopy, 10 dogs had both 
gastroduodenoscopy and colonoscopy, and colonoscopy alone was performed in 5 
dogs. Sixty-eight intestinal mucosal biopsies were collected by endoscopy from four 
different segments of the intestinal tract of above-mentioned dogs, namely 





5.2 Mucosal MMP-2 and -9 activities in healthy Beagle dogs 
(study I) 
 
Gelatin zymography was performed with 48 mucosal samples from four different 
intestinal segments (duodenum, jejunum, ileum, and colon) of 12 healthy Beagles. 
When positive, it showed gelatinolytic activity at the same level as the positive 
control bands of pro-MMP-2 and -9 and was therefore considered to represent canine 
pro-MMP-2 and pro-MMP-9 (Fig. 6). Since the majority of samples containing 10 
μg of total protein showed no activity (pro-MMP-2: 40/48, 83%; pro-MMP-9: 33/48, 
69%), only the results for samples containing 25 μg of total protein are presented 
here. Pro-MMP-2 and -9 activities were found in 17/48 (35%) and 25/48 (52%) of 
the samples, respectively. None of the intestinal samples showed gelatinolytic 
activity corresponding to the control bands of active MMP-2 and MMP-9.
Using McNemar test, no significant difference was found for pro-MMP-2 and -9 
activities between the four separate parts of the intestine (duodenum, jejunum, ileum 
and colon) (P > 0.05). However, for pro-MMP-2, the number (and percentage) of 
positive samples in four different parts of the intestine of 12 dogs were from the 
highest to the lowest as follows: ileum, 7/12 (58.3%); jejunum, 5/12 (41.7%); 
duodenum, 3/12 (25%); and colon, 2/12 (16.7%). For pro-MMP-9, ileum had the 
highest positivity rate (8/12; 66.7%), followed by jejunum (6/12; 50%), duodenum 
(6/12; 50%), and colon (5/12; 41.7%). From all 48 canine intestinal mucosa samples 
examined with zymography, no pro-MMP-2 and -9 activity was found in 31/48 
(65%) and 23/48 (48%), respectively. 
The enzyme activities ranged for pro-MMP-2 between 0.015 and 6.449 AU and 
for pro-MMP-9 between 0.018 and 5.680 AU. In the examined four different parts of 
the intestine, the median (range) pro-MMP-2 activity was from the highest to the 
lowest: ileum, 0.175 (0-3.337) AU; jejunum, 0 (0-6.449) AU; duodenum, 0 (0-4.301) 
AU; and colon, 0 (0-0.146) AU. The highest pro-MMP-9 activity [median and range] 
was found in the ileum (0.086 [0-1.443] AU), followed by colon (0.018 [0-1.652] 
AU), jejunum (0.011 [0-2.810] AU) and duodenum (0 [0-5.680] AU). In the majority 
of positive samples (36/42; 86%), either pro-MMP-2 or -9 activities were lower than 
2 AU throughout the whole intestine (Table 2). Comparably high activities (AU ≥ 2) 
of pro-MMP-2 were recorded in two mucosa samples from duodenum and jejunum, 
as well as one ileum. Two duodenal mucosa samples and one jejunum sample 







Fig.6. Representative zymogram from intestinal mucosa samples of healthy Beagles (25 μg 
protein). Recombinant human pro- and active MMP-2 (lane 2) and -9 (lane 1), pro-MMP-2 


























































































































   
   
   
   








































































































































































































































5.3 Mucosal measuring MMP-2 and -9 activities in dogs with 
CE (study III)  
 
Zymographic analyses revealed that gelatinolytic activities in positive samples were 
at the same molecular weights as the positive control bands of pro- and active MMP-
2 and -9, and were therefore considered to represent canine pro- and active MMP-2
and -9 (Fig. 7). The median and range of mucosal pro- and active MMP-2 and -9 
activities in each intestinal segment in dogs with CE and healthy Beagles are shown 
in Table 3.
In the duodenum, dogs with CE compared to healthy Beagles had a significantly 
higher number [and percentage] of samples positive for mucosal pro-MMP-2 (32/35 
[91.4%] vs. 3/18 [16.7%]; P < 0.0001), active MMP-2 (10/35 [28.6%] vs. 0/18 [0%]; 
P = 0.0108), and pro MMP-9 (34/35 [97.1%] vs. 10/18 [55.6%]; P = 0.0004) (Fig. 
8). For active MMP-9, two positive samples were recorded in dogs with CE 
compared to none in healthy Beagles, but this difference was not significant (2/35 
[5.7%] vs. 0/18 [0%]; P = 0.5428) (Fig. 8). None of the intestinal mucosal samples 
in healthy Beagles showed gelatinolytic activity corresponding to the control bands 
of active MMP-2 and -9.   
In the ileum, dogs with CE compared to healthy Beagles had significantly higher 
numbers [and percentage] of samples positive for mucosal pro-MMP-2 (11/12 
[91.7%] vs. 6/18 [33.3%]; P = 0.0024) and active MMP-2 (4/12 [33.3%] vs. 0/18 
[0%]; P = 0.0181; Fig. 9). For pro- and active MMP-9, dogs with CE had more 
positive samples compared to healthy Beagles, but the differences were not 
significant (11/12 [91.7%] vs. 11/18 [61.1%], P = 0.0994 and 3/12 [25%] vs. 0/18 
[0%]; P = 0.0542, respectively) (Fig. 9).
In the colon, dogs with CE compared to healthy Beagles had significantly higher 
number [and percentage] of samples positive for mucosal pro-MMP-2 (13/15 
[86.7%] vs. 3/18 [16.7%]; P < 0.0001), active MMP-2 (7/15 [46.7%] vs. 0/18 [0%]; 
P = 0.0015), and pro-MMP-9 (15/15 [100%] vs. 8/18 [44.4%]; P = 0.0005, Fig. 10). 
In dogs with CE only, however, one had active MMP-9 positive samples compared 
to healthy Beagles with none and the difference was not significant (1/15 [6.7%] vs. 
0/18 [0%]; P = 0.4545) (Fig. 10).  
In the cecum, despite a higher percentage of samples positive for pro- and active 
MMP-2 and -9 in dogs with CE compared to healthy Beagles, the differences 







Table 3. Mucosal pro- and active MMP-2 and -9 activities in dogs with CE and healthy 
Beagles. Pro- and active MMP-2 and -9 activities were measured in the mucosal samples 
from duodenum, ileum, colon, and cecum of dogs with CE and healthy Beagles. AU: arbitrary 
units; CE: chronic enteropathies; Pro: pro-enzyme
Intestinal 
part           
   














Duodenum Dogs with CE 
(n = 35)
 




0 (0–0.64) 0 (0–0) 0.03 (0–3.32) 0 (0–0)
Ileum Dogs with CE 
(n = 12)
 




0 (0–0.52) 0 (0–0) 0.03 (0–0.45) 0 (0–0)
Colon Dogs with CE 
(n = 15)
 




0 (0–0.64) 0 (0–0) 0 (0–0.79) 0 (0–0)
Cecum Dogs with CE 
(n = 6)
 
0.0 (0.01–1.48) 0 (0–0.01) 0.09 (0.02–0.59) 0.005 (0–0.05)
Healthy Beagles
(n = 6)
0 (0–0.3) 0 (0–0) 0.18 (0–0.82) 0 (0–0)
 
 
Fig. 7. Representative zymogram from intestinal mucosa samples (10 μg protein).
Recombinant human pro- and active MMP-2 (lane 2) and -9 (lane 1), pro- and active MMP-
2 and -9 positive samples in dogs with CE (lanes 3–4), pro-MMP-2 and -9 positive samples 





Fig. 8. The presence of samples positive for pro- and active MMP-2 and -9 in the duodenal 
mucosa of dogs with CE and healthy Beagles. P-values are based on the comparison of pro- 
and active MMP-2 and-9 activities in the duodenum of dogs with CE versus healthy 








Fig. 9. The presence of samples positive for pro- and active MMP-2 and -9 in the ileal 
mucosa of dogs with CE and healthy Beagles. P-values are based on the comparison of pro- 
and active MMP-2 and-9 activities in the ileum of dogs with CE versus healthy Beagles. 
(Study III) 
P < 0.0001 
P = 0.0108 
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Fig. 10. The presence of samples positive for pro- and active MMP-2 and -9 in the colonic 
mucosa of dogs with CE and healthy Beagles. P-values are based on the comparison of pro- 








Fig. 11. The presence of samples positive for pro- and active MMP-2 and -9 in the cecal 
mucosa of dogs with CE and healthy Beagles. Despite a higher percentage of samples 
positive for pro- and active MMP-2 and -9 in cecal samples in dogs with CE compared to 
healthy Beagles, the differences between them did not reach statistical significance. (Study 
III) 
P < 0.0001  
P = 0.0015 
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5.4 Mucosal S100A12 concentrations in healthy Beagle dogs 
(study II)  
The S100A12 concentration in all samples ranged from 2.5 to 237.6 μg/L. In the 
four different parts of the intestine examined in 12 healthy Beagles, the highest 
median levels of S100A12, which were significant, were found in the ileum (71.5 
μg/L [38.9–141.9]), followed by the colon (23.2 μg/L [6.7–75.6]), duodenum (11.4 
μg/L [6.9–28.5]), and jejunum (8.5 μg/L [5.1–19.3]) (Table 4 and Fig. 12). In 




Table 4. Distribution of S100A12 concentrations and MPO activities in the intestinal 






1 2 3 4 5 6 7 8 9 10 11 12
Duodenum S100A12 
(μg/L)
6.0 27.9 7.3 5.4 27.0 45.8 28.7 14.0 30.3 8.7 6.7 8.0
MPO 
(ΔA/min)
0.61 0.35 0.46 0.03 0.17 0.09 0.70 0.08 0.11 0.62 0.54 0.10
Jejunum S100A12 
(μg/L)
7.3 22.1 2.5 5.0 31.3 20.8 9.6 5.5 11.9 5.8 2.7 14.8
MPO 
(ΔA/min)
5.12 1.04 2.15 0.22 0.26 0.32 1.92 0.37 0.22 0.35 0.85 0.36
Ileum S100A12 
(μg/L)
38.1 143.0 41.2 18.3 91.6 209.6 138.4 90.8 237.6 52.1 44.1 20.0
MPO 
(ΔA/min)
0.18 1.14 1.25 0.16 0.80 1.33 1.43 0.18 0.22 0.72 0.55 0.28
Colon S100A12 
(μg/L)
11.5 123.4 64.4 5.2 79.3 57.6 4.2 6.8 34.9 94.4 6.6 7.0
MPO 
(ΔA/min)





Fig. 12. Boxplot representing the log-transformed S100A12 concentrations in the intestinal 
mucosa samples of 12 healthy Beagles. The horizontal line inside each box represents the 
median; the top and bottom of each box represent the 75th and 25th percentiles, 
respectively; and the whiskers represent the 95th and 5th percentiles. *P < 0.05 vs. 
duodenum, jejunum, and colon; #P < 0.05 vs. jejunum. (Study II)
5.5 Mucosal S100A12 concentrations in dogs with CE (study 
IV) 
 
Mucosal S100A12 concentrations in each intestinal segment in dogs with CE and 
healthy Beagles are shown in Figure 13. The median (IQR) of mucosal S100A12 
concentrations in dogs with CE were significantly higher than those in healthy 
Beagles in the duodenum (43.93 [23.62–78.03] vs. 11.86 [7.66–29.1] μg/L; p <
0.0001) and colon (63.04 [33.53–211.53] vs. 15.94 [6.95–59.3] μg/L; P = 0.0011). 
Even though dogs with CE had higher mucosal S100A12 concentrations than healthy 
Beagles in the ileum (118.54 [47.26-142.9] vs. 48.1 [24.87-91.4] μg/L; P = 0.2725) 
and cecum (160.38 [43.27-326.28] vs. 33.53 [27.97-38.01] μg/L; P = 0.2194), these







Fig. 13. Scatter plot displaying log-transformed intestinal mucosal S100A12 concentrations 
in CE dogs and healthy Beagles. Data are expressed as the mean ± standard deviation. 
Individual data points are shown by triangles (samples from healthy Beagles) and circles 
(samples from CE dogs).  CE: chronic enteropathies; **P < 0.01 vs. healthy colon; #P <




5.6 Analytical validation of spectrophotometric method for 
MPO measurement (study II)
The intra-assay coefficients of variation (CV%) in six different small intestinal 
mucosa samples assayed in a 1:2 dilution were 0.77, 0.85, 1.80, 1.56, 0.64, and 
1.02%, and were 1.55, 1.84, 1.24, 1.30, 1.03, and 1.03% in six different large 
intestinal mucosa samples tested in a 1:2 dilution. The inter-assay CV% for six 
different small intestinal and six different large intestinal mucosa samples assayed in 
a 1:2 dilution were 1.77, 0.37, 2.55, 2.24, 1.32, and 2.59%, and 7.00, 7.59, 1.76, 
2.74, 1.00, and 1.66%. 
The observed to expected ratios (O/E) at dilutions of 1:2, 1:4, 1:8, and 1:16 
ranged from 91.6–106.9% (mean ± SD: 98.3 ± 3.8%) for six different small 
intestinal mucosa samples, and from 84–103.8% (93.6 ± 4.9%) for six different large 
intestinal mucosa samples. O/E for the spiking recovery ranged from 97.3–111.1% 
(103.7 ± 4.8%) for five different small intestinal mucosa samples, and from 90.2–




5.7 Mucosal MPO activity in healthy Beagle dogs (study II) 
 
The MPO enzyme activity was determined in all mucosal samples from four 
different intestinal areas of 12 healthy Beagles. The median MPO activity was 
significantly higher in the ileum (0.49 ΔA/min [0.19–1.05]), jejunum (0.36 ΔA/min 
[0.28–1.70]) and duodenum (0.26 ΔA/min [0.09–0.59]) than in the colon (0.09 
ΔA/min [0.04–0.14]) (P < 0.05) (Table 4 and Fig. 14). In addition, the difference 




Fig. 14. Boxplot representing the log-transformed MPO activities in the intestinal mucosal 
samples of 12 healthy Beagles. The horizontal line inside each box represents the median; 
the top and bottom of each box represent the 75th and 25th percentiles, respectively; and the 




5.8 Mucosal MPO activity in dogs with CE (study IV) 
 
Mucosal MPO enzyme activity in each intestinal segment in dogs with CE and 
healthy Beagles are shown in Figure 15. The median (IQR) of mucosal MPO activity 
of dogs with CE was significantly higher than the corresponding activity in healthy 
Beagles in the duodenum (1.3 [0.77–2.16] vs. 0.41 [0.11–0.64] ΔA/min; P <
0.0001), ileum (1.91 [0.72–2.83] vs. 0.75 [0.21–1.27] ΔA/min; P = 0.0083), colon 
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(1.46 [0.57–3.01 vs. 0.09 [0.03–0.17] ΔA/min; P < 0.0001] ΔA/min), and cecum 




Fig. 15. Scatter plot displaying log-transformed intestinal mucosal MPO activity in CE dogs 
and healthy Beagles. Data are expressed as the mean ± standard deviation. Individual data 
points are shown by triangles (samples from healthy Beagles) and circles (samples from CE 
dogs) CE: chronic enteropathies; *P < 0.05 vs. healthy cecum; **P < 0.01 vs. healthy ileum; 
#P < 0.0001 vs. healthy duodenum and colon. (Study IV)
5.9 Histological examination  
5.9.1 Healthy Beagle dogs (study I-II)
 
Based on the histological examination of the intestine, the median total WSAVA 
score of all samples was 0 (range 0–3) classifying all findings as insignificant. There 
were no histological abnormalities in the submucosa, the muscularis externa, and the 
serosa in any of the samples.  
5.9.2 Healthy Beagle dogs (study III-IV) 
 
Based on the histological examination of intestinal samples from healthy Beagles, 
the median total WSAVA score of all samples was 0 (range 0–4), classifying all 




5.9.3 Mucosal MMP-2 and -9 activities in relation to histopathologic changes 
in dogs with CE (study III)
 
In the ileum, pro-MMP-2 activities were significantly higher in mucosal samples 
with normal epithelium (P = 0.0317) and lamina propria neutrophil score (P = 
0.0335). There was a positive significant association between the active MMP-2 
activities with the severity of lamina propria eosinophil scores in cecal samples (P =
0.0339). The association of active MMP-9 activities with the severity of lamina 
propria neutrophil scores in the duodenum (P = 0.0398), and the severity of lamina 
propria eosinophil infiltration scores in the cecum (P = 0.0369) were significantly 
positive. Active MMP-9 activities were also significantly higher in cecal samples 
with normal lamina propria lymphocytes/plasmacell scores (P = 0.0491).
 
5.9.4 Mucosal S100A12 concentrations in relation to histopathologic changes 
in dogs with CE (study IV) 
 
Mucosal S100A12 concentrations showed a significant association with the severity 
of macrophage infiltration in the duodenum of dogs with CE (Table 5, P = 0.0439). 
In addition, the median (IQR) of duodenal mucosal S100A12 concentrations were 
significantly higher if the inflammatory infiltrate contained neutrophils 61.1 [19.51-
179.60] vs. 42.72 [7.41-102.46] μg/L; P = 0.037). However, when S100A12 
concentrations were compared among the severity groups (normal, mild, moderate, 
and severe) of neutrophilic infiltration in the duodenum, there was no significant 
association in dogs with CE (Table 5, P = 0.1542). However, mucosal S100A12 
concentrations were numerically higher in those with mild, moderate, or severe 
neutrophilic infiltration than in those with no neutrophilic infiltration. In addition, no 
significant association was found between S100A12 concentrations and severity of 
neutrophilic infiltration in the ileum, colon, and cecum of dogs with CE. In the 
colon, mucosal S100A12 concentrations showed a significant association with the 
severity of epithelial injury and total histopathologic injury (Table 6, P < 0.05). 
 
5.9.5 Mucosal MPO activity in relation to histopathologic changes in dogs 
with CE (study IV) 
 
Higher mucosal MPO activity showed a significant association with severity of total 
histopathologic injury, epithelial injury, and eosinophilic infiltration in the 
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duodenum (Table 5, P < 0.05). In the duodenum of dogs with CE, mucosal MPO 
activity was numerically higher in samples with moderate and severe neutrophilic 
infiltration than in samples with mild or no neutrophilic infiltration (Table 5). 










































Table 5. Association between mucosal S100A12 concentrations and MPO activities with 
severity of histopathological findings in the duodenum and ileum of dogs with CE. 
Statistical differences were calculated based on the log-transformed values of S100A12 and 
MPO. Untransformed values are reported as median (IQR).
Histopathological 
findings












35 Insignificant (n = 16)
Mild (n = 15)











Villus stunting 35 Normal (n = 20)
Mild (n = 10)
Moderate (n = 3)










Epithelial injury 35 Normal (n = 30)
Mild (n = 3)








Crypt distension 35 Normal (n = 29)
Mild (n = 5)








Lacteal dilation 35 Normal (n = 19)
Mild (n = 10)








Mucosal fibrosis 35 Normal (n = 31)









35 Normal (n = 23)
Mild (n = 10)








Lamina propria LPC 35 Normal (n = 2)
Mild (n = 15)
Moderate (n = 15)












35 Normal (n = 22)
Mild (n = 5)










35 Normal (n = 20)
Mild (n = 7)
Moderate (n = 6)












35 Normal (n = 32)










12 Insignificant (n = 8)









Villus stunting 12 Normal (n = 7)






Epithelial injury 12 Normal (n = 10)






Crypt distension 12 Normal (n = 11)






Lacteal dilation 12 Normal (n = 8)










12 Normal (n = 6)








n: sample size; IQR: interquartile range; LPC: lymphocytes/plasma cells; # ANOVA test after logarithmic 









Lamina propria LPC 12 Normal (n = 4)
Mild (n = 4)










12 Normal (n = 9)
Mild (n = 2)










12 Normal (n = 9)








12 Normal (n = 12) 118.54 (9.59-317.21) - 1.91 (0.34-7.01) -
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Table 6. Association between mucosal S100A12 concentrations and MPO activities with 
severity of histopathological findings in the colon and cecum of dogs with CE. Statistical 
differences were calculated based on the log-transformed values of S100A12 and MPO. 
Untransformed values are reported as median (IQR). 
Histopathological 
findings












15 Insignificant (n = 7)
Mild (n = 7)











Epithelial injury 15 Normal (n = 8)
Mild (n = 3)
Moderate (n = 3)










Crypt hyperplasia 15 Normal (n = 11)
Mild (n = 3)








Crypt dilation and 
distortion
15 Normal (n = 12)








15 Normal (n = 8)
Mild (n = 5)
Moderate (n = 1)















15 Normal (n = 2)
Mild (n = 9)
Moderate (n = 3)












15 Normal (n = 9)
Mild (n = 3)










15 Normal (n = 10)
Mild (n = 4)



















Epithelial injury 6 Normal (n = 3)






Crypt hyperplasia 6 Normal (n = 5)






Crypt dilation and 
distortion
6 Normal (n = 5)














6 Normal (n = 2)








6 Normal (n = 3)








6 Normal (n = 5)








6 Normal (n = 6) 160.38 (8.62-405.48) - 0.68 (0.12-1.66) -
n: sample size; IQR: interquartile range; LPC: lymphocytes/plasma cells; # ANOVA test after logarithmic 




5.10 Mucosal MMP-2 and -9 activities, S100A12 
concentrations, and MPO activities in relation to CIBDAI 
and clinical outcome (study III-IV) 
 
Based on treatment response after diet change or antibiotic or corticosteroid therapy, 
the outcomes of 30 dogs with CE were classified as follows: 10 dogs with FRE, 4 
dogs with ARE, 13 dogs with SRE, and 3 dogs with SNRE. The median (range) of 
CIBDAI scores before and after treatment and the type of clinical outcome are 
summarized in Table 7. For pro- and active MMP-2 and -9, only active MMP-9
activities in the ileal mucosa had a strong positive correlation with the CIBDAI score 
before treatment in dogs with CE (r = 0.71, P = 0.023). In dogs with CE, no 
significant association was found between the mucosal pro- and active MMP-2 and -
9 activities and the clinical outcome in each intestinal segment (data not shown, P >
0.05). In addition, no significant association was evident between mucosal S100A12 
concentrations or MPO activities with CIBDAI scores before treatment or in the 
clinical outcome for each intestinal segment in dogs with CE (data not shown, P >
0.05). 
Steroid non-responsive dogs (SNRE, n = 3) either died or were euthanized due to 
severe clinical signs and unfavorable response to treatments. When comparing 
duodenal samples, the median (range) of the CIBDAI score before treatment was 
higher in SNRE dogs (n = 3) than in SRE dogs (n = 12) (7 [4–7] vs. 4.5 [0–7]). 
Hypoalbuminemia (<20 g/L) was present in 1/3 SNRE and 2/12 SRE dogs. The 
median (range) of total histopathological injury score of SNRE dogs was 7 (5-7) and 
SRE dogs was 6 (1-11). The median (range) of the pro- and active MMP-2 and -9 
activities in the duodenal mucosa of SNRE dogs compared to SRE dogs were as 
follows: pro-MMP-2 (0.01 [0–0.02] AU vs. 0.01 [0–1.66] AU), active MMP-2 (0 [0–
0.01] AU vs. 0 [0–0.01] AU), pro-MMP-9 (0.07 [0.02–0.16] AU vs. 0.09 [0–3.86] 
AU), and active MMP-9 (0 [0–0.21] AU vs. 0 [0–0] AU. The median (range) of 
mucosal S100A12 concentrations and MPO activities in SNRE dogs compared to 
SRE dogs were as follows in the duodenum: (53.12 [19.51-93.02] g/L vs. 42.97 
[12.49-179.6] g/L and (1.22 [0.77-1.58] ΔA/min vs. 1.21 [0.14-17.6] ΔA/min,
respectively. The number of SNRE dogs was too low for statistical analysis other 
than descriptive comparison.  
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Table 7. Clinical outcome related to CIBDAI score before and after treatment in CE 
dogs. 
 
5.11 Mucosal MMP-2 and -9 activities, S100A12 
concentrations, and MPO activities in relation to 
hypoalbuminemia in dogs with CE (study III-IV) 
 
Out of 40 dogs, 36 (90%) had normoalbuminemia with a median (range) serum 
albumin concentration of 32.7 g/L (24.9-39 g/L). However, four dogs (10%) had 
hypoalbuminemia with a median (range) serum albumin concentration of 12.2 g/L 
(11-13 g/L). Duodenal mucosal biopsies were taken from the four hypoalbuminemic 
dogs and correlation between the mucosal MMP-2 and -9 activities, S100A12 
concentrations, and MPO activities in the duodenum and hypoalbuminemia were 
evaluated. 
In study III, there was no significant correlation between pro-MMP-2 (r = -
0.165, P = 0.345), active MMP-2 (r = -0.15, P = 0.389), pro-MMP-9 (r = -0.146, P
= 0.402), or active MMP-9 (r = -0.024, P = 0.893) activities in the duodenal mucosa 
and hypoalbuminemia in dogs with CE. In hypoalbuminemic compared to 
normoalbuminemic dogs with CE, the number [percentage] of positive samples in
the duodenal mucosa was as follows: pro-MMP-2 (3/4 [75%] vs. 29/31 [93.5%]);
active MMP-2 (1/4 [25%] vs. 9/31 [29%]; P < 0.01); pro-MMP-9 (3/4 [75%] vs. 
31/31 [100%]); and active MMP-9 (1/4 [25%] vs. 1/31 [3.2%]). The median (range) 
of the pro- and active MMP-2 and -9 activities in the duodenal mucosa of 
hypoalbuminemic dogs with CE compared to normoalbuminemic dogs with CE was
as follows: pro-MMP-2 (0.01 [0–0.017] AU vs. 0.01 [0–1.66] AU); active MMP-2
(0 [0–0.01] AU vs. 0 [0–0.02] AU); pro-MMP-9 (0.14 [0–0.74] AU vs. 0.05 [0.01–
3.86] AU); and active MMP-9 (0 [0–0.21] AU vs. 0 [0–0.1] AU. 
In study IV, the median (IQR) of mucosal S100A12 concentrations and MPO 
activities in hypoalbuminemic dogs with CE compared to normoalbuminemic dogs 















13 4 (0-7) 0 (0-1)
Steroid non-responsive 
enteropathy (SNRE)
3 7 (4-9) 9 (4-10)
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were as follows: 128.94 [69.54-175.91] g/L vs. 42.72 [23.62-61.1] g/L and 1.55 
[0.81-3.14] ΔA/min vs. 1.58 [0.81-2.9] ΔA/min, respectively. Since the number of 
hypoalbuminemic dogs was too low for meaningful statistical analysis, we reported 
the results descriptively.
5.12 Correlation between S100A12 concentrations and MPO 
activities (study IV) 
A moderate positive correlation between mucosal S100A12 concentrations and MPO 
activities was seen in dogs with CE and healthy Beagles combined (r = 0.392; P <
0.0001); this correlation was also observed in healthy Beagles alone (r = 0.327; P =
0.011). However, there was no correlation between mucosal S100A12 
concentrations and MPO activities in dogs with CE alone (p = 0.273) or in the 
different intestinal segments from dogs with CE (duodenum: p = 0.0949; ileum: p =




6.1 Identification of mucosal MMP-2 and -9 activities in the 
intestine of healthy Beagles using gelatin zymography 
(study I)  
 
In study I, MMP-2 and -9 were detected in four different sections of the intestinal 
mucosa of healthy Beagle dogs with a gelatin zymography method. The method has 
been used previously to study MMP-2 and -9 in human intestinal samples (Kleiner 
and Stetler-Stevenson, 1994; Baugh et al., 1999; Gao et al., 2005), but no known 
similar studies have yet been made from canine intestinal mucosal. In this study (I), 
stored intestinal mucosal samples were used, that had been collected during necropsy 
from 12 healthy Beagle dogs after finishing another non-related study to avoid the 
unnecessary use of laboratory animals for experimental studies. The collected 
samples were then stored at -80 C for later research. This approach complies with 
the principles of replacement, reduction, and refinement of animal experiments 
(Flecknell, 2002). It seems unlikely that the previous studies could have interfered 
with our results since all dogs had the same living and nutritional conditions and 
were clinically healthy at the time of euthanasia. In addition, the histological 
examination of the intestinal mucosa was a part of our study to investigate the 
possibility of subclinical intestinal inflammation which might have influence on the 
interpretation of the study results. 
Gelatin zymography is a highly sensitive technique and is widely used in the 
determination of MMP-2 and -9 in tissue samples. This technique appears to be a 
useful method for the evaluation of intestinal mucosa samples, because it requires 
only a small piece of intestinal tissue sample (5 mg mucosa) which is the weight of 
about 1-2 endoscopically taken biopsies. This technique can detect even small 
amounts of MMP-2 and -9 from tissue-homogenization supernatant (Snoek-van 
Beurden and Von den Hoff, 2005). The gelatin zymography used here was described 
by Rajamäki et al. (2002), selecting both 10 and 25 μg of total protein in the 
extracted samples. The amount of 10 μg protein is often used in human IBD research 
for determination of MMPs by gelatin zymography. However, the majority of 
samples in this study that contained 10 μg of total protein showed no activity. It is 
likely that the levels of MMP-2 and -9 activities in healthy Beagles are too low to be 
detected in 10 μg protein samples in comparison to 25 μg protein samples. 
Therefore, only the results for samples containing 25 μg of total protein are 
presented in this thesis for the characterization of MMP-2 and -9 in the intestinal 
mucosa of healthy Beagles. To assess whether higher protein amounts lead to MMP 
detection in negative samples, larger protein amounts of 100 μg were tested, but 
these also gave negative results. 
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In the canine samples, the zymography method produced distinct bands on the 
gel which corresponded to the standards with human pro-MMP-2 and -9. No
substantial difference was detected between the migration of these enzymes from 
human standards and intestinal mucosa samples obtained from healthy Beagles, 
which is in accordance with MMP-2 and -9 enzymes being highly conserved among 
species (Coughlan et al., 1998). 
In study I, 65% and 48% of all samples showed no activity for pro-MMP-2 and -
9, respectively, and the colon showed the lowest activity. One possible reason for the 
high amount of undetectable activity might be that the level of gelatinolytic activity 
of both MMPs was less than the detection limit of the gelatin zymography assay. 
Similar results were reported for normal human colon mucosa samples. In the study 
by Baugh et al. (1999), pro-MMP-2 and -9 were not detected in 20% and 56% of 
their samples, respectively, using gelatin zymography when examining colon 
mucosa from nine healthy human subjects. In study I, no intestinal samples showed 
gelatinolytic activity corresponding to the control bands of active MMP-2 and MMP-
9. Similarly, Baugh et al. (1999) detected no active forms of MMP-2 and -9 in 
healthy human colonic mucosa samples.  
Thirty-five percent (17/48) of the samples were positive for pro-MMP-2 activity 
in study I. In healthy Beagles, pro-MMP-2 activity was mostly seen in the small 
intestine. This might be due to high levels of epithelial cell turnover in the small 
intestine (Bergman et al., 2002). MMP-2 is commonly expressed in normal intestinal 
tissues and is believed to participate in the maintenance of collagen homeostasis and 
intestinal tissue remodeling (Gao et al., 2005; Sengupta and MacDonald, 2007). Pro-
MMP-9 activity was detected in 52% (25/48) of the samples. Under normal 
conditions, MMPs including MMP-9 are expressed at low levels, usually in the pro-
form, and when activated, they play a role in normal tissue ECM turnover, including 
intestinal tissue (Medina and Radomski, 2006). 
Gao et al. (2005) reported the mean (± SEM) activities of pro-MMP-2 and pro-
MMP-9 in normal colonic mucosa of humans to be < 2 AU with 0.64 ± 0.1 and 1.18 
± 0.19 AU, respectively. The majority of samples of study I (86%) also displayed 
pro-MMP-2 and -9 activities < 2 AU; however, some histologically unremarkable 
samples showed comparably high pro-MMP-2 and -9 activities > 2 AU, for which 
there is no clear explanation.   
The activity of MMP-2 and MMP-9 in different parts of the intestinal mucosa of 
healthy Beagles has been determined in study I, laying the groundwork for further 
studies in canine chronic enteropathies. Pro-MMP-2 and -9 activities were found in 
the intestinal mucosa of the small and large intestines in healthy Beagles, mostly in 
the ileum. Active forms of MMP-2 and -9 were not detected in the intestinal mucosa 
of healthy Beagles. These findings raised the question whether MMP-2 and -9 are 
also involved in the pathogenesis of canine CE. Therefore, we collected intestinal 
mucosal biopsy samples from dogs with CE in study III to investigate their activities 
in the mucosa. 
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6.2 Mucosal MMP-2 and -9 activities in the intestine of dogs 
with CE (study III)  
This thesis outlines the first known report on mucosal MMP-2 and -9 activities in the 
intestine of dogs with CE (Study III). In this study, the number of samples positive 
for pro- and active MMP-2 and pro-MMP-9 was higher in the mucosa of dogs with 
CE compared to healthy Beagles in all intestinal segments when determined by
gelatin zymography. Similar findings were also reported for active MMP-2 and pro-
MMP-9 in the colonic mucosa of humans with IBD compared to healthy controls 
(Baugh et al., 1999). In Study III, a significantly higher percentage of colonic 
mucosal samples in dogs with CE had pro-MMP-2 activity compared to healthy 
Beagles (86.7% vs. 16.7%). However, the percentage of samples with colonic 
mucosal pro-MMP-2 activity was the same in human patients with IBD and healthy 
controls, and activity was detected in 80% of the samples (Baugh et al., 1999). 
Active MMP-2 was detected in 46.7% of the colonic samples of dogs with CE,
however, no activity was found in colonic mucosal samples of healthy Beagles. 
Similarly, Baugh et al. (1999) detect no active MMP-2 activities in the colonic 
mucosa of healthy humans, but did observe active MMP-2 activities in 35% of 
human IBD samples. Under normal conditions, MMP-2 is believed to participate in 
the maintenance of collagen homeostasis and intestinal tissue remodeling. In human 
IBD, MMP-2 has been reported to contribute to ECM remodeling and the 
degradation of basal membrane type IV collagen, leading to intestinal ulceration, 
epithelial damage, and/or fistula formation (Stallmach et al., 2000; Matsuno et al., 
2003; McKaig et al., 2003; Gao et al., 2005; O'Sullivan et al., 2015). It appears that 
intestinal tissue turnover is increased during intestinal inflammation, tissue 
destruction, and healing processes, and demands greater MMP-2 activities in human 
IBD (Gao et al., 2005). In contrast, it has been reported that MMP-2 plays a 
protective role against tissue damage, possibly through the regulation of epithelial 
barrier function, in an MMP-2 knockout mouse model of IBD (Garg et al., 2006; 
Ravi et al., 2007; Garg et al., 2009). In our study (III), it appears that having higher 
activities of pro- and active MMP-2 in dogs with CE indicates the possible 
involvement of this enzyme in the pathogenesis of canine chronic enteropathies. In 
addition, we showed that the samples with higher pro-MMP-2 activities have an 
association with a normal epithelium and lamina propria without neutrophils in the 
ileum. Similar to the study on an MMP-2 knockout mouse model of IBD, it is 
possible that MMP-2 holds a protective role against tissue damage through the
regulation of epithelial barrier function in dogs; however, more research is needed to 
clarify the role of MMP-2 in canine CE.  
Mucosal pro-MMP-9 was detected in more than 90% of the samples in the 
intestinal segments of dogs with CE, while this form of enzyme was detected in 33% 
to 61% of the intestinal mucosal samples of healthy Beagles. Therefore, pro-MMP-9 
activities are elevated in dogs with CE compared to healthy Beagles, which is similar 
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to the findings of Baugh et al. (1999) in humans with IBD. Nonetheless, no active 
form of MMP-9 was found in the mucosa of healthy Beagles in this study (study III), 
which is similar to the findings reported in the colonic mucosa of healthy humans 
(Baugh et al., 1999). In dogs with CE, the active form of MMP-9 was detected in 
5.7%, 25%, 5.6%, and 50% of duodenal, ileal, colonic, and cecal samples, 
respectively. In the duodenal and cecal samples, a positive and significant 
association was evident between active MMP-9 activities and the severity of lamina 
propria neutrophilic and eosinophilic infiltration, with these cells being proposed as 
sources of MMP-9. In comparison to human IBD, the percentage of active MMP-9-
positive samples in the colon of dogs with CE was much lower (55% vs. 5.6%)  
(Baugh et al., 1999). This difference could be due to the different pathophysiology of 
canine and human chronic colitis. A higher number of infiltrated neutrophils and 
more ulcerative lesions in humans with chronic colitis could be the possible reasons 
for the higher active MMP-9 activities in humans (Gao et al., 2005). In future 
studies, immunohistochemistry should also be included to assess the localization of 
MMP-2 and -9 in the intestinal mucosa and their correlation with intestinal 
pathologies in dogs. 
A positive correlation was found between active MMP-9 activities in the ileal 
mucosa and CIBDAI score before treatment in dogs with CE, which is similar to the 
relationship between mucosal MMP-9 and disease activity index in a rat model of 
colitis (Oliveira et al., 2014), and between fecal MMP-9 and clinical activities of 
ulcerative colitis in humans (Farkas et al., 2015).  However, due to the low number 
of active MMP-9 positive samples (n = 3) in the ileal samples of dogs with CE in our 
study, the results should not be over-interpreted. In the present study, we did not find 
a significant association between mucosal pro- and active MMP-2 and -9 activities 
and the type of clinical outcome in each intestinal segment in dogs with CE. One 
possible reason could be the low number of samples in some groups (Table 7) and 
because of assessing the relationship between the mucosal MMP -2 and -9 activities 
and type of clinical outcome in each intestinal segment of dogs with CE.  
The association between an aberrant intestinal expression of MMP-2 and -9 and 
human IBD is now well established (O'Shea and Smith, 2014). MMP-2 and -9 have 
been investigated as biomarkers and diagnostic tool for human IBD. The level of 
fecal MMP-9 in UC patients correlates with disease activity and has recently been 
proposed as a biomarker of the disease. By measuring fecal MMP-9 levels, it was 
possible to distinguish UC from diarrhea predominant irritable bowel syndrome with 
85% sensitivity and 100% specificity (Dabritz et al., 2014). Serum level of MMP-9
has also been shown as a potential tool in the prediction of CD activity status in 
children (Kofla-Dlubacz et al., 2012).  In addition, MMP-2 and MMP-9 levels in 
urine of pediatric patients with IBD have been reported as useful novel non-invasive
biomarkers to predict CD and UC independently in children (O'Shea and Smith, 
2014).  Our study is the first to demonstrate an upregulation of mucosal pro- and 
active MMP-2 and pro-MMP-9 in the intestine of dogs with CE. This is a promising 
indication that MMPs play a role in canine CE with the potential of being used as 
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biomarkers of active disease and disease severity. In the present study, however, we 
did not find a significant association between mucosal MMP-2 and -9 activities and 
the type of clinical outcome in dogs with CE which could be due to  the low number 
of dogs with a certain clinical outcome (especially SNRE dogs, n = 3). In addition, 
the comparison between intestinal segments led to rather low case numbers when 
assessing the association between mucosal MMP-2 and -9 activities with the type of 
clinical outcome. Further studies with sufficient number of canine patients in each 
types of CE is needed to evaluate the relationship between MMP-2 and -9 activities 
and canine CE subtypes. MMP expression in the intestine or elsewhere in the body, 
e.g. serum or feces, may in the future help in properly differentiating disease 
subtypes and severity, and to enable tailored treatment choices for individuals. 
A unique therapeutic option for human IBD is targeting MMPs which has been 
investigated in animal models of IBD. Inhibition of MMPs with non-selective 
inhibitors (e.g. Marimastat, Batimastat) has been shown to reduce mucosal damage 
and colitis induced by dextran sodium sulfate (Tyden et al.) in animal models 
(O'Shea and Smith, 2014).  However, the development of MMP inhibitors in humans 
has been limited by their poor selectivity (O'Shea and Smith, 2014). To target 
MMPs, monoclonal antibodies against MMP-2 and MMP-9 have been developed 
and tested on murine models of IBD. These antibodies were significantly reducing 
the severity of the DSS induced colitis in mice (Sela-Passwell et al., 2011; O'Shea 
and Smith, 2014). However, due to the myriad roles of MMPs in vivo and their 
ubiquitous expression throughout the body, using monoclonal antibodies remains a 
serious concern and a barrier to their current therapeutic use in human IBD (O'Shea 
and Smith, 2014). Whether targeting MMPs using monoclonal antibodies in canine 
CE patients is beneficial for CE treatment is not known yet and needs to be studied. 
It has been shown that treatment of human IBD with immunosuppressive 
medications could reduce the levels of MMPs in the intestinal mucosa and serum.
Makitalo et al. (Makitalo et al., 2009) showed in people that the treatment of CD
patients with anti-TNF- α therapy (infliximab or adalimumab) or with corticosteroids 
and other immunosuppressive drugs (methotrexate or azathioprine) decreased 
stromal MMP-9 and epithelial MMP- 7 as assessed by immunohistochemistry 
methods. However, there are different reports regarding the response of MMP-9 to 
therapy in serum. Gao et al. (Gao et al., 2007) reported that serum levels of MMP-9
decrease in adults in response to infliximab therapy; however, Makitalo et al. 
(Makitalo et al., 2012) reported no significant changes in serum MMP-9 levels after 
therapy. In mice, magniferin, a bioactive compound of the mango, attenuated DSS
induced colitis through directly reducing the activity of mucosal TNF-α and MMP-9
(Somani et al., 2016). Future studies in CE dogs should be planned as treatment 
follow up studies with repeated biopsies to evaluate the treatment effects of different 
medication especially immunosuppressive drugs such as prednisolone on the 
intestinal mucosal MMP-2 and -9 activities.
In study III, no significant correlations were evident between pro- and active 
MMP-2 and -9 activities in the duodenal mucosa and hypoalbuminemia in dogs with 
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CE. Since only 10% (4/40) of the dogs had hypoalbuminemia (<20 g/L), the number 
of samples was too low for an appropriate power of analysis and it could be the
reason why we did not find significant correlations between MMP2 and 9 activities. 
In humans, to our knowledge, there has been so far no report studying MMP-2 and -
9 activities in patients with protein losing enteropathies.  In future prospective 
studies, the necessary number of cases of CE dogs with hypoalbuminemia should be 
estimated by using power analysis, for which the data of the current study are 
helpful.  
6.3 Determination of mucosal S100A12 concentrations and 
MPO activities in the intestine of healthy Beagles (study 
II)  
In study II, mucosal S100A12 concentrations and MPO activities in four different 
segments of intestine in healthy Beagle dogs were determined by an ELISA and a 
spectrophotometric method, respectively. The ELISA method was already validated 
for determination of S100A12 concentrations in the serum and fecal samples of 
healthy Beagles and dogs with IBD (Heilmann et al., 2016a), but not in canine 
intestinal mucosal extracts. Concentrations of S100A12 were higher in mucosal 
extracts from the ileum than in other segments of the intestine in healthy Beagles. 
S100A12 detection in the intestinal mucosa may reflect the number of neutrophils 
infiltrating the mucosa. Because of poor agreement between pathologists evaluating 
the number of duodenal neutrophils (Willard et al., 2010), no attempt was made to 
perform neutrophil count comparisons between the different intestinal sections. 
Therefore, the higher S100A12 concentrations in the ileum may be due to the high 
number of S100A12-expressing cells (neutrophils and macrophages) within the ileal 
mucosa. Heilmann et al. reported variations in the fecal concentrations of S100A12 
in healthy dogs (Heilmann et al., 2011a). An irregular distribution of S100A12-
expressing cells within the gastrointestinal mucosa or variation in the concentration 
of fecal proteins due to variations in the gastrointestinal passage were suggested as 
possible reasons for this variation (Heilmann et al., 2011a). Moreover, Heilmann et 
al. reported a similar variation in other fecal markers in healthy dogs (Heilmann et 
al., 2008; Heilmann et al., 2011b). In study II, the S100A12 concentration in all 
mucosal extracts ranged from 2.5–237.6 μg/L. Similar variations in the S100A12
concentration were reported for normal duodenal and cecal mucosal biopsies in 
humans (Leach et al., 2007). In a study by Leach et al., duodenal and cecal biopsies 
were cultured and supernatants were collected for the determination of S100A12 
using an ELISA method. In that study, the S100A12 concentration ranged from 7–36
μg/L in the culture supernatants of duodenal and cecal mucosal biopsies obtained 
from 33 non-IBD control children (Leach et al., 2007). A similar variation was also 
found in the concentration of calprotectin, another member of the S100/calgranulin 
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protein family, ranging from 16–511 μg/L in the culture supernatants of duodenal 
and cecal mucosal biopsies (Leach et al., 2007).  
In study II, a spectrophotometric method to measure MPO activity in the 
intestinal mucosa in healthy Beagles was successfully established and validated for 
the first time. Mucosal MPO activity was higher in the ileum, jejunum, and 
duodenum than in the colon of healthy Beagles. Moreover, its activity was higher in 
the jejunum than in the duodenum. The detection of MPO in the intestinal mucosa 
could reflect the number of granulocytes infiltrating the mucosa. Variations in the 
MPO activity in different parts of the intestine in healthy Beagles could be explained 
by the disparity in the distribution of MPO-releasing cells, such as the neutrophils 
and macrophages. Several previous studies have investigated the distribution of 
immune cells in the intestines of healthy dogs and cats (German et al., 1999; Waly et 
al., 2001; Kleinschmidt et al., 2008; Siddique et al., 2009; Marsilio et al., 2011).
However, the results did not allow for conclusions concerning the distribution of 
MPO, since the distribution of neutrophils as the primary source of MPO was not 
studied. Macrophages, as a possible source of MPO, were detected using the 
antibody MAC387 in two studies of the intestines of normal cats (Waly et al., 2001) 
and dogs (Siddique et al., 2009). The authors concluded that the number of MAC387 
positive cells was higher in the ileum than in other segments of the intestine. 
However, no known study has been performed to address the distribution of the 
MPO enzyme in different parts of the normal intestinal mucosa of dogs or any other 
species. 
Several studies reported increased levels of both S100A12 and MPO in human 
patients with IBD (Foell et al., 2003b; de Jong et al., 2006; Kayo et al., 2006; Kaiser 
et al., 2007; Leach et al., 2007; Peterson et al., 2007; Foell et al., 2008; Sidler et al., 
2008; Wagner et al., 2008; Hegazy and El-Bedewy, 2010; Dabritz et al., 2013). 
However, studies determining S100A12 and MPO in intestinal mucosal samples 
from dogs suffering from CE remain unreported. Fecal S100A12 concentrations 
have been reported to be increased in dogs with CE compared to healthy Beagles 
(Heilmann et al., 2014a). Whilst using non-invasive biomarkers is more appropriate 
in determining the presence of gut inflammation, measuring the fecal S100A12 
concentration does not allow for the assessment of the specific part of the intestine 
from which the S100A12 sample originates. Fecal S100A12 may be valuable for 
screening dogs suspected of having chronic enteropathies and for monitoring disease 
activity, thus reducing the need for endoscopy during disease follow-up. Increases in 
fecal S100A12 are, therefore, viewed as indicative of endoscopy, rather than being 
used as an alternative to endoscopy for diagnosis (de Jong et al., 2006). In study II, 
laboratory methods were validated to determine the biomarkers in tissues from their 
proposed origin. Both mucosal S100A12 and MPO may be valuable markers 
complementing invasive diagnostic measures when used in combination with 
intestinal mucosal histology. This is an important basis for the study of the role of 




6.4 Mucosal S100A12 concentrations and MPO activities in 
the intestine of dogs with CE (study IV)  
 
In study IV, we reported mucosal S100A12 concentrations and MPO activities in the 
intestine of dogs with CE. The results of study IV showed that the mucosal S100A12 
concentrations are significantly higher in dogs with CE than in healthy Beagles in 
the duodenum and colon (Fig. 13). In the ileum and cecum, mucosal S100A12 
concentrations were numerically higher in dogs with CE than those in healthy 
Beagles. However, this difference did not reach statistical significance (Fig. 13). The 
results of our investigation in the duodenum are consistent with those from Leach et 
al. in humans with IBD (Leach et al., 2007). In that study, duodenal and cecal 
biopsies of children with IBD (including UC, CD, or unclassified IBD) were 
cultured and supernatants were collected for ELISA determination of S100A12 
concentrations. Similar to the results of study IV, children with UC, CD, or 
unclassified IBD had significantly higher S100A12 concentrations in the culture 
supernatants of duodenal and cecal mucosal biopsies than those in non-IBD control 
children (Leach et al., 2007). In another similar study in humans, Foell et al. (Foell et 
al., 2008) also found higher S100A12 concentrations in culture supernatants of 
colonic and ileal biopsy samples in patients with active CD than in those patients 
with inactive CD or healthy controls. In addition, higher S100A12 concentrations 
were found in culture supernatants of colonic samples in patients with active UC 
than in those patients with inactive UC or healthy controls. Similar to Foell et al. 
(2008), significantly higher S100A12 concentrations were evident in colonic 
samples from dogs with CE than those in healthy Beagles (Study IV). However, in 
contrast to humans with CD, despite higher mucosal S100A12 concentrations in ileal 
samples of dogs with CE compared with healthy Beagles, this difference did not 
reach statistical significance. Heilmann et al. (Heilmann et al., 2014a) previously 
reported significant upregulation of fecal S100A12 concentration in dogs with CE 
compared with healthy Beagles, which is consistent with our results in the duodenum 
and colon (study IV). 
Colonic mucosal S100A12 concentrations significantly associated with the 
severity of epithelial injury and total histopathological injury in dogs with CE (Table 
6). When S100A12 binds to RAGE, an inflammatory response occurs due to the 
production of pro-inflammatory cytokines via activation of NF-κB, which ultimately 
leads to tissue damage (Hofmann et al., 1999; Foell et al., 2007; Pietzsch and 
Hoppmann, 2009). In the current study, higher mucosal S100A12 concentrations 
were found if the inflammatory infiltrate had a neutrophil or macrophage 
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component. This is consistent with the findings in human patients with IBD (Foell et 
al., 2003b). However, since only 3 dogs had mild macrophage infiltration, the results 
should not be over interpreted and rather be a sign that more research needs to be 
performed with macrophage specific staining.  In dogs with CE, however, Heilmann 
et al. (Heilmann et al., 2014a) did not observe a significant association between fecal 
S100A12 and the presence of neutrophils and macrophages in the intestinal mucosal 
biopsies or with the site(s) of inflammatory lesions. It is challenging to correlate 
fecal S100A12 concentrations to the site(s) of inflammatory lesions and cellular 
infiltrates within the GI tract, as it is unclear from which part of the intestine the 
S100A12 protein originates. Fecal S100A12 can be considered as reflective for 
mucosal S100A12 concentration giving an indication for the need to localize the site 
of the inflammatory lesions within the GI tract and to identify the areas most 
affected by the disease process. In addition to standard histology, mucosal 
biomarkers could provide valuable information concerning localization, severity and 
possible pathogenesis of inflammatory processes.  
In study IV, mucosal MPO activity was significantly higher in all studied 
segments of the intestine of dogs with CE than the corresponding activity in healthy 
Beagles (Fig. 15). Similar results were also observed in the colonic mucosa of 
humans with IBD (Kruidenier et al., 2003; Kayo et al., 2006; Hegazy and El-
Bedewy, 2010; Hansberry et al., 2017) and in animal models of human IBD (Kim et 
al., 2012; Li et al., 2016; Lv et al., 2017). In addition to the bactericidal activity of 
MPO products in activated phagocytes, there is considerable evidence that 
inappropriate or excessive stimulation of oxidant formation by this enzyme can 
result in host tissue damage (Davies, 2011). In the present study, mucosal MPO 
activity showed a significant association with severity of epithelial injury and total 
histopathological injury in the duodenum of dogs with CE (Table 5), which is
consistent with findings in humans with IBD (Kruidenier et al., 2003; Kayo et al., 
2006) and also in animal models of human IBD (Kim et al., 2012). The most severe 
histopathological injuries observed in mucosal samples with higher MPO activity
could be explained by MPO-induced oxidative tissue damage in the inflamed 
mucosa. In addition, mucosal MPO activity showed a significant association only 
with eosinophil infiltration but not with neutrophil infiltration in the duodenum. 
Although MPO activity levels were numerically higher in samples with moderate 
and severe neutrophilic infiltration than those with mild or no neutrophilic 
infiltration in the duodenum of dogs with CE, these differences were not statistically 
significant (Table 5). In future studies, immunohistochemistry can be used to 
localize S100A12 and MPO cellular origin more specifically in the intestinal mucosa 
of dogs with CE. 
In study IV, no significant association was found between mucosal S100A12 
concentrations or MPO activities in each intestinal segment with CIBDAI score 
before treatment or CE type (ie, FRE, ARE, SRE, or SNRE). Similarly in children 
with IBD, mucosal S100A12 concentrations were not associated with the pediatric 
Crohn’s disease activity index (PCDAI) (Leach et al., 2007). However, these 
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findings contrast with the study of Heilmann et al. (Heilmann et al., 2014a), who 
found a significant correlation between fecal S100A12 and the canine chronic 
enteropathy clinical activity index (CCECAI). It should be taken into consideration 
that CIBDAI or CCECAI include a number of subjective elements and consequently 
do not always represent the actual inflammatory burden, which may lead to 
discordance between the results of this study with others. In contrast to the reported 
results (Study IV), another study by Heilmann et al. (Heilmann et al., 2016b)
revealed elevated fecal S100A12 concentrations in dogs with SRD compared with 
those with FRD or ARD. Elevated fecal S100A12 concentrations were also observed 
in SNRD dogs compared with those in dogs that underwent complete remission. One 
of the limitations of study IV is that we did not measure S100A12 concentrations in 
the feces of dogs with CE to assess for any associations between fecal S100A12 
concentrations and types of clinical outcome. Accordingly, direct comparisons 
between our results and those with of Heilmann et al. (Heilmann et al., 2016b) are 
not possible. One possible reason why a significant association between these 
biomarkers and clinical outcome was not observed might be the small number of 
samples from dogs with a certain clinical outcome (especially SNRE dogs, n = 3) 
(Table 3). Also the comparison between intestinal segments led to rather low case 
numbers when assessing the association between mucosal S100A12 concentrations 
and MPO activities with the type of clinical outcome.  
Duodenal S100A12 concentrations were higher in four hypoalbuminemic dogs
with CE. However, due to the low number of hypoalbuminemic dogs in our study, 
the clinical significance of our results is not clear. However, Heilmann et al. did not 
find a significant association between fecal S100A12 concentrations and 
hypoalbuminemia (<20 g/L) in dogs with CE despite numerically higher fecal 
S100A12 concentrations in dogs with hypoalbuminemia (Heilmann et al., 2014a).
Our findings suggest that further studies are warranted in more severely affected 
patients and should include measurements of both fecal and mucosal S100A12 
concentrations.
In study IV, a moderate positive correlation was observed between mucosal 
S100A12 concentrations and MPO activities in dogs with CE and healthy Beagles 
combined and also in healthy Beagles alone. However, no correlation was found in 
dogs with CE alone and also when analyzing different intestinal segments of dogs 
with CE. In pediatric studies, a moderate positive correlation was found between 
mucosal S100A12 and calprotectin concentrations only in non-IBD controls but not 
in patients with IBD (Leach et al., 2007). Given that both S100A12 and MPO are 
derived predominantly from neutrophils, a correlation between the two biomarkers in 
dogs with CE was expected. Possible reasons for not having this correlation could be 
that two different methods were used to measure S100A12 concentrations and MPO 




In the study III and IV, we used stored intestinal mucosal samples from both 
diseased and healthy Beagle dogs. In the case of healthy Beagle dogs, the samples 
were collected during post-mortem examinations after finishing other non-related 
studies to avoid the unnecessary use of laboratory animals for experimental 
proposes. This methodology complies with the principles of replacement, reduction 
and refinement of animal experiments (Flecknell, 2002). As this approach requires 
long-term stability of the measured analytes, we checked the MPO activity in 14 
randomly chosen mucosal supernatant samples before and after 3 years of storage at 
-80ºC. The median (range) of MPO activity at the first measurement (0.35 ΔA/min 
(0.01-1.92)) and after 3 years of storage at -80ºC (0.35 ΔA/min (0.004-2.19)) were 
not statistically different (P = 0.101), which shows long-term stability of MPO 
activity in mucosal supernatant samples. Concentrations of S100A12 in fecal 
extracts stored frozen at -80°C have also been shown to be stable for years 
(Heilmann RM, unpublished data) and it is reasonable to assume that the same holds 
true for mucosal specimens. In addition, in our study, the control dogs were intact 
and older Beagles, however, it is rather unlikely that breed, gender, age, or being 
castrated or intact has an influence on our results. Age had also no influence on 




6.5.1 Study I and II
 
In some occasional histological samples in study I, it was impossible to interpret 
epithelial changes due to processing artifact. However, since several samples were 
used per location for histology, there was enough epithelial layer on the majority of 
samples from the same intestinal segment of every dog to allow a final 
interpretation.  The submucosa, muscularis, and serosa were not affected by artifacts. 
6.5.2 Study III and IV
 
One of the limitations in study III and IV was too low number of CE dogs with
hypoalbuminemia (<20 g/L) for an appropriate power of analysis. In future
prospective studies, the necessary case numbers of CE dogs with hypoalbuminemia 
should be prospectively estimated.
In addition, S100A12 concentrations were not measured in the feces of dogs with 
CE to assess for any associations between fecal S100A12 concentrations and types 
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of clinical outcome (study IV). Another limitation of our study is that the cobalamin 
and folate concentrations were not measured in a sufficient number of dogs with CE 
to allow statistical analysis. Therefore, future prospective studies need to include a 
variety of laboratory data to assess possible associations/correlations. Finally, the 
treatment follow up was not standardized in study III and IV which should be 
considered when planning future studies. 
 
6.6 Further research
Further research is needed to assess the localization of MMP-2 and -9 in 
canine intestinal mucosa, their presence and activity level in advanced CE 
with intestinal protein loss, and their relation to the other inflammatory 
markers in canine chronic enteropathies.  
In the future, it will also be necessary to focus more on advanced cases with 
intestinal protein loss, a patient group that was underrepresented in this study 
and also looking for other MMPs. 
MMP-2 and -9 activities in fecal samples should be determined to study their 
possible usefulness as non-invasive biomarkers of intestinal inflammation 
(Annahazi et al., 2013; Pujada et al., 2016).  
In humans, several studies have investigated the role of other MMPs (e.g., 
MMP-1, MMP-3, MMP-7, MMP-10) and their inhibitors (e.g., TIMP-1, 
TIMP-3) in the pathogenesis of human IBD (von Lampe et al., 2000; 
Matsuno et al., 2003; Ravi et al., 2007; Mäkitalo, 2010). Studies are therefore
warranted to determine those MMPs and TIMPs activities also in the 
intestinal mucosa of canine CE.  
In the future, it is needed to assess the value of measuring mucosal S100A12 
concentrations and MPO activities in clinical practice, and also their relation 
to fecal S100A12 and MPO as well as other inflammatory markers in dogs 





Based on these studies, the following conclusions can be drawn:  
1. Based on the results of Study I and reports from studies in human patients 
with IBD, zymography presents as an appropriate method to evaluate MMP-
2- and -9 profiles in canine intestinal mucosa.  
2. Study II showed that S100A12 and MPO are reliably detectable in canine 
intestinal mucosa using the ELISA and spectrophotometric methods. The 
assays used appeared to be sufficient to further evaluate the role of S100A12 
and MPO in the pathogenesis of canine chronic enteropathies. 
3. Study III showed an upregulation of mucosal pro- and active MMP-2 and 
pro-MMP-9 in the intestine of dogs with CE compared to healthy Beagles.
Compared to human patients with IBD, the active form of MMP-9 has been 
detected in a rather small number of canine patients which could be due to 
low number of granulocytes found in the intestinal mucosa of dogs with CE.
The results, however, provide supporting evidence for the possible 
involvement of MMP-2 and -9 in the pathogenesis of canine CE. 
4. The results of Study IV showed that both mucosal S100A12 concentrations 
and MPO activities are significantly increased in the duodenum and colon of 
dogs with CE, with mucosal MPO being also increased in the ileum and 
cecum. In study IV, mucosal S100A12 concentrations in dogs with CE 
correlated with the severity of epithelial injury and total histopathological 
injury in the colon; and with the presence of neutrophils and macrophages in 
the duodenal mucosa or with hypoalbuminemia. In addition, mucosal MPO 
activity is associated with the severity of epithelial injury and total 
histopathological injury in the duodenum of dogs with CE. The results also 
provide supporting evidence for the utility of mucosal S100A12 and MPO as 
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